

SYNTHESIS OF 1-DEOXY-N,N-BIS-DEMETHYL-PYRROMYCIN (10),  
METHYL 3-N-(BENZYL-CARBOXAMIDO)-2,3,4,6-  
TETRADEOXY-DL-THREO-HEXOPYRANOSE (78) AND ITS 3-EPIMER (80)

by

© YULIN YAN

B.Sc. (Equivalent) China Pharmaceutical University

A Thesis Submitted to the Faculty of Graduate Studies  
and Research of the University of Manitoba  
in Partial Fulfillment of the Requirement for  
the Degree of Master of Science  
in the Department of Chemistry

Sept., 1988

Permission has been granted to the National Library of Canada to microfilm this thesis and to lend or sell copies of the film.

The author (copyright owner) has reserved other publication rights, and neither the thesis nor extensive extracts from it may be printed or otherwise reproduced without his/her written permission.

L'autorisation a été accordée à la Bibliothèque nationale du Canada de microfilmer cette thèse et de prêter ou de vendre des exemplaires du film.

L'auteur (titulaire du droit d'auteur) se réserve les autres droits de publication; ni la thèse ni de longs extraits de celle-ci ne doivent être imprimés ou autrement reproduits sans son autorisation écrite.

ISBN 0-315-51643-7

SYNTHESIS OF 1-DEOXY-N,N-BIS-DEMETHYL-PYRROMYCIN (10),  
METHYL 3-N-(BENZYL-CARBOXAMIDO)-2,3,4,6-TETRADEOXY-  
DL-THREO-HEXOPYRANOSE (78) AND ITS 3-EPIMER (80)

BY

YULIN YAN

A thesis submitted to the Faculty of Graduate Studies of  
the University of Manitoba in partial fulfillment of the requirements  
of the degree of

MASTER OF SCIENCE

© 1989

Permission has been granted to the LIBRARY OF THE UNIVER-  
SITY OF MANITOBA to lend or sell copies of this thesis, to  
the NATIONAL LIBRARY OF CANADA to microfilm this  
thesis and to lend or sell copies of the film, and UNIVERSITY  
MICROFILMS to publish an abstract of this thesis.

The author reserves other publication rights, and neither the  
thesis nor extensive extracts from it may be printed or other-  
wise reproduced without the author's written permission.

### ACKNOWLEDGEMENTS

The author expresses his sincere thanks to Dr. C. M. Wong for his guidance and patience while doing the work presented in this thesis. The author would also like to express his thanks to Dr. Peter H. Y. Lam, from the University of Manitoba's Department of Medicine, for the biological activity tests. Thanks are also due to Ms. Huiyin Liu who developed some of the processes in the aminosugar synthesis.

The financial support by the University of Manitoba is deeply appreciated by the author.

## ABSTRACT

A new anthracycline, 1-deoxy-N,N-bis-demethyl-pyrromycin (10) was synthesized by coupling natural aklavinone (55) with protected 1-bromo- (49) and 1-chloro-aminosugar (50) under Koenigs-Knorr condition. The coupling process is highly stereoselective presumably due to the formation of the 7-membered ring nitrobenzoyloxonium intermediate (59) to give the  $\alpha$ -oriented glycoside (56) as the predominant product.

Aklavinone (55) was obtained by acid hydrolysis of a pigment compound isolated from the culture of *Streptomyces Galilaeus* Var. *Siwenensis* (68). The structural assignment of (55) was achieved by comparison of all chemical and physical data with literature values and further proved by high resolution p.m.r. spectrum (Fig. 1B) which is not available in the literature. The structures of compounds 56 and 57 were also unambiguously assigned by their two dimensional p.m.r. spectrum (Figs. 5B),  $^{13}\text{C}$  spectrum (Fig. 5D) and high resolution p.m.r. spectrum (Fig. 6B) as well.

1-Deoxy-N,N-bis-demethyl-pyrromycin (10) shows remarkable antitumor activity comparable to those of adriamycin (2) and aclacinomycin A (6), (1).

Compound methyl 3-N-(benzyl-carboxamido)-2,3,4,6-tetra-deoxy-DL-threo-hexopyranose (78) and its 3-epimer 80, are considered as intermediates for the total synthesis of novel aminosugars 2,3,4,6-tetra-deoxy-3-N-aminomethyl-DL-threo-hexopyranose (92) and 2,3,4,6-tetra-3-N-aminomethyl-DL-erythro-hexopyranose (93). Intermediates

78 and 80 were also converted to new aminosugars 86 and 87.

The structures, relative stereochemistry and the preferred conformations of the four anomers, 82, 83, 84 and 85 of the key intermediates 78 and 80 were positively determined by detailed examination of their infrared spectra, (Figs. 14A, 15A, 17A and 18A), high resolution p.m.r. spectra (Figs. 14B, 15B, 17B and 18B) and mass spectra, (Figs. 14C, 15C, 17C and 18C), including high resolution mass spectra, (Figs. 14D, 15D, 17D, 18D).

## TABLE OF CONTENTS


1. Introduction
2. Results and Discussions
  - 1) Part A: Synthesis of 1-Deoxy-N,N-bis-demethyl pyrromycin (10).
  - 2) Part B: Synthesis of Methyl 3-N-(benzyl-carboxamido)-2,3,4,6-tetra-deoxy-DL-threo-hexopyranose (78) and its 3-Epimer (80).
3. Experiment
  - 1) Part A: Synthesis of 1-Deoxy-N,N-bis-demethyl-pyrromycin (10).
  - 2) Part B: Synthesis of Methyl 3-N-(benzyl-carboxamido)-2,3,4,6-tetra-deoxy-DL-threo-hexopyranose (78) and its 3-epimer (80).
4. Spectra
  - 1) Infrared
  - 2) Nuclear Magnetic Resonance
  - 3) Mass Spectra
5. Reference

## INTRODUCTION


The work on the antitumor anthracyclines can be traced back to the late 1950's (2). Later on, rhodomycin A (4) and B (5), pyrromycin (9), cinerubins A (8), aklavin (7), and other anthracyclines were separated and characterized (3). Among this class of pigmented substances antibiotic and antitumor activity was only displayed by the glycosides. A detailed review of studies of the anthracyclines during 1950's was given by Brockmann (3).

In 1961, daunomycin (1) was isolated from a culture of *Streptomyces peucetius* (4). Some other daunomycin related analogues had also been isolated from microbial culture, such as carminomycin (3), (7), and duborimycin (8). The biological antitumor activities of daunomycin (1), which demonstrated superiority over the previously known anthracyclines such as rhodomycin A (4) and B (5), motivated the elucidation of the structural features of daunomycin and its analogues.


The research strategy, concerned with the development of new anthracycline analogues with more potent antitumor activities and/or less cardiotoxicities than daunomycin (1), were originally carried out on two lines: one having purpose of investigations of structure, stereochemistry and structure-activity relationship; and the other having the purpose of search for new biosynthetic analogues in cultures. These approaches essentially resulted in the isolation and characterization of adriamycin (2) in 1968 (5), aclacinomycin A (6) in




|              |     | R <sub>1</sub>  | R <sub>2</sub> |
|--------------|-----|-----------------|----------------|
| Daunomycin   | (1) | CH <sub>3</sub> | H              |
| Adriamycin   | (2) | CH <sub>3</sub> | OH             |
| Carminomycin | (3) | H               | H              |
|              |     | R               |                |
| Rhodomycin A | (4) | X               |                |
| Rhodomycin B | (5) | H               |                |




X =





|  |      | $R_1$ | $R_2$ | $R_3$  | $R_4$  |
|--|------|-------|-------|--------|--------|
| Aclacinomycin A                          | (6)  | H     | Y     | $CH_3$ | $CH_3$ |
| Aklavin                                  | (7)  | H     | H     | $CH_3$ | $CH_3$ |
| Cinerubin A                              | (8)  | OH    | Y     | $CH_3$ | $CH_3$ |
| Pyrrromycin                              | (9)  | OH    | H     | $CH_3$ | $CH_3$ |
| 1-Deoxy-N,N-bis-<br>demethyl-pyrrromycin | (10) | H     | H     | H      | H      |


Y =




1975 (6) and the development of some new synthetic analogues which displayed better biological antitumor activities and/or less cardiotoxicities than daunomycin (1).

Daunomycin (1), as well as adriamycin (2) and aclacinomycin A (6), are being used clinically in the treatment of acute leukemia and solid tumors in man. Unfortunately, these compounds have some undesirable side effects, the most serious being dose-related cardiotoxicities to various extents (9), which hampers their therapeutical applications. However, such dose related cardiotoxicities are not observed with the administration of other anticancer drugs (10).

The mechanisms of antitumor properties of these drugs seem to be related with anthracycline glycoside-DNA intercalation (11), bioreductive alkylation (12), and anthracycline glycoside-cell surface interaction (13). The X-ray diffraction study of the daunomycin-DNA complex revealed that the daunomycin aglycone chromophore in the DNA complex is oriented at right angles to the long axis between base pairs of DNA. The ring D rests in the minor groove of the double helix (14). The oxygen on C<sub>7</sub> is in a quasi axial position in which the oxygen is projected further away. Consequently the oxygen on C<sub>7</sub> and the hydroxy hydrogen on C<sub>9</sub> can no longer form an intramolecular hydrogen bond, in contrast to those observed in other crystal structures of anthracycline antibiotics, (14, 15). The C<sub>9</sub>-OH forms hydrogen bonds with the nitrogens of an adjacent base in DNA double helix (14). Interestingly, in a series of related anthracycline glycoside drugs, the cardiotoxicity can not be related



|                       |      | R <sub>1</sub>   | R <sub>2</sub> | R <sub>3</sub> | R <sub>4</sub> | R <sub>5</sub> | R <sub>6</sub>  | R <sub>7</sub>  |
|-----------------------|------|------------------|----------------|----------------|----------------|----------------|-----------------|-----------------|
| 4-Demethoxy-          |      |                  |                |                |                |                |                 |                 |
| daunomycin            | (11) | H                | OH             | H              | OH             | H              | H               | H               |
| 4-Demethoxyadriamycin | (12) | H                | OH             | OH             | OH             | H              | H               | H               |
| 11-Deoxydaunomycin    | (13) | OCH <sub>3</sub> | H              | H              | OH             | H              | H               | H               |
| 11-Deoxyadriamycin    | (14) | OCH <sub>3</sub> | H              | OH             | OH             | H              | H               | H               |
| 4'-Epi-daunomycin     | (15) | OCH <sub>3</sub> | OH             | H              | H              | OH             | H               | H               |
| 4'-Epiadriamycin      | (16) | OCH <sub>3</sub> | OH             | OH             | H              | OH             | H               | H               |
| 4'-Deoxydaunomycin    | (17) | OCH <sub>3</sub> | OH             | H              | H              | H              | H               | H               |
| 4'-Deoxyadriamycin    | (18) | OCH <sub>3</sub> | OH             | H              | H              | H              | H               | H               |
| N,N-Dimethyl-         |      |                  |                |                |                |                |                 |                 |
| daunomycin            | (19) | OCH <sub>3</sub> | OH             | H              | H              | H              | CH <sub>3</sub> | CH <sub>3</sub> |



(19)

to the antitumor activity, suggesting a unique mode of action (16). Some reports suggested correlation of this cardiotoxicity with an anthracycline glycoside-mitochondrial membrane interaction (17). In terms of biochemistry, the cardiotoxicity is assumed to be a consequence of a redox process involving the quinone moiety of the aglycone which generates superoxide and hydroxide radicals.

These radicals are highly toxic to the heart cell in which superoxide dismutase or catalase concentration is very low compared to the liver and kidney cells (18). In addition, mutagenicity did not seem to relate with the cytotoxic activity, e.g. antitumor activity, (19).

The chemical investigation of new analogues of daunomycin (1) mainly focuses on four objectives: 1) structural and stereochemical investigations of anthracyclines; 2) modification and total syntheses of aglycone moieties; 3) modification and total syntheses of aminosugar moieties; and 4) methodology of coupling aglycones with aminosugar moieties. So far more than 500 analogues of daunomycin have been synthesized or isolated from nature and tested for biological activity, (20).

#### 1) Structural and Stereochemical Investigations of Anthracyclines

The structural and stereochemical investigations of the anthracyclines show that the site on C<sub>9</sub> in ring D bears the two different carbon atom side chain, either an acetyl group in daunomycin or an ethyl group with an extra carbomethoxy side chain on C<sub>10</sub> in aclacinomycin A. In addition, a tertiary hydroxy on C<sub>9</sub> and secondary hydroxy on C<sub>7</sub> have a cis geometry relationship with each

other. All of these are characteristic features of the anthracyclines with significant antitumor activity. Furthermore, ring D contains the site of sugar attachment, e.g. the benzylic position at C<sub>7</sub>. Therefore two asymmetric centers at C<sub>9</sub> and C<sub>7</sub> reside in ring D of daunomycin (1) and adriamycin (2). Aclacinomycin A (6) has an extra asymmetric centre at C<sub>10</sub>. The formation of a hydrogen bond between the hydroxy group on C<sub>9</sub> and oxygen atom on C<sub>7</sub>, which was confirmed by X-ray diffraction studies of anthracycline, apparently stabilized the half-chair conformation (24) of ring D (Fig.1).






Fig. 1 The Half-chair Conformation of Ring D in Adriamycin (15).


Daunosamine (21) and rhodosamine (22), present in anthracycline antibiotics, are L-lyxo-hexoses with  $\alpha$ -glycosidic linkages to the C7 benzylic position. Four chiral centers in these aminosugars are assigned the 1'(R), 3'(S), 4'(S) and 5'(S) configuration corresponding to  $\alpha$ -glycosidic linked glycosides. The  $\alpha$ -glycosides may show




daunosamine (21)




rhodosamine (22)




acosamine (23)




vancosamine (24)




L-megosamine (25)




angolosamine (26)




actinosamine (27)




ristosamine (28)




4-deoxydaunosamine (29)



4-deoxyristosamine (30)




(31)




(32)

X = COC<sub>6</sub>H<sub>4</sub>NO<sub>2</sub>




Y = Me



(19a) X =



(19b) X =




(19c)

antitumor activities while  $\beta$ -isomers are only weakly active or completely inactive (40). The special feature of Daunosamine (21), (3-amino-2,3,6-trideoxy-L-lyxo-hexopyranose), with the configurational and structural differences from other aminosugars present in anthracyclines, seems to account for the remarkable antitumor activity of the anthracycline glycosides, such as daunomycin (1) and adriamycin (2). In addition to daunosamine (21), other 3-amino-2,3,6-trideoxy hexoses such as L-rhodamine (22), 3-N,N-dimethylamino-2,3,6-trideoxy-L-lyxo-hexopyranose, from rhodomycin and Aklavin (6); acosamine (23), 3-amino-2,3,6-trideoxy-L-arabino-hexopyranose, from actinoidin; vancosamine (24), 3-amino-3-C-methyl-2,3,6-trideoxy-L-lyxo-hexopyranose, from vancomycin; L-megosamine (25), 3-dimethylamino-2,3,6-trideoxy-L-ribo-hexopyranose, from megalomycins; angolosamine (26), 3-dimethylamino-2,3,6-trideoxy-D-arabino-hexopyranose, from angolamycin; actinosamine (27), 3-amino-4-O-methyl-2,3,6-trideoxy-L-arabino-hexopyranose, from actinoidin and ristosamine (28); 3-amino-2,3,6-trideoxy-L-ribo-hexopyranose, from ristomycin, have been found as components of other antibiotic molecules.


## 2). Modification and Total Synthesis of Aglycone Moieties

A huge number of chemically modified analogues of the antitumor anthracyclines have been obtained by exploration of the reactivity of analogues modified in ring D substitution and those modified in the anthraquinone chromophore (21), such as 19c. The modifications of ring D were mainly focused on: the modification of the side chains on C<sub>13</sub> and C<sub>14</sub> by oxidative degradation; the variation of the side




(33) X = SO<sub>2</sub>

(33a) X = SO



(34) X = SO<sub>2</sub>

(34a) X = SO



(35)

chains at C<sub>9</sub> and C<sub>10</sub>; the substitution at C<sub>8</sub>; and construction of a new skeleton of ring D. Modification of the quinone moiety and the anthraquinone chromophore at positions of C<sub>4</sub>, C<sub>6</sub> and C<sub>11</sub> were also investigated extensively by: a) synthesis of 4-demethoxydaunomycin (11), 4-demethoxyadriamycin (12), 11-deoxydaunomycin (13), 11-deoxyadriamycin (14), the 6-O-methyl and the 11-O-methyl derivatives; b) replacement of 4-O-methyl with other alkyl groups; and c) the modification of the quinone moiety (21) and the skeleton of ring D (22, 23).

Some significant results of structure-activity-toxicity study are worth mentioning. Alternation of the groups attached to C<sub>9</sub> produced profound effects on the biological antitumor activities (20). Absence of 4-methoxy or 11-hydroxy groups seemed to display higher anticancer activity and/or lower cardiotoxicity (25). The quinone moiety seems to be responsible for both antitumor activity and cardiotoxicity (20b). A summary of studies on anthracyclines during the 1960's and 1970's was given by F. Acarmone (4c).


The total syntheses of the aglycone moieties of daunomycin, adriamycin, aclacinomycin A and their analogues have also been extensively studied (4c, 26-36). The first total synthesis of daunomycinone (20) in 1971 and heteroanthracyclines, such as, 6,7,9,11-tetrahydroxy-9-acetyl-7,8,9,10-tetrahydrobenzo(b)thioxanthen-12-one-5-oxide (33a), the 5-dioxide analogue 33; their corresponding regioisomers 34a and 34 in 1984; and the aglycone 35 with five membered ring D in 1987 were reported by Wong and coworkers, (22, 33, 37, 38). The total syntheses of anthracyclines, while quite different in

conception, all involved the construction of either ring B or C from a bicyclic precursor as a key step. The challenge related to the construction of the aglycone is: the regiospecific connection of the ring A to the CD unit; the functionalization of ring D; and the stereospecific introduction of two hydroxy groups on C<sub>9</sub>, C<sub>7</sub> and-COOCH<sub>3</sub> on C<sub>10</sub> in the case of aklavinone.

### 3) Modification and Total Syntheses of Aminosugar Moieties

The presence of the aminosugar residue in the anthracycline antibiotics is an important structural requirement for biological activity, since biological activity of the isolated aglycone moiety has never been reported. The results also indicate that the mutagenesis of anthracycline is closely related to the structure difference in the sugar moiety (19). The 3'-amino groups in the anthracycline analogues are involved in electrostatic interaction between the aminosugar and the phosphate groups of DNA (39) and therefore are responsible for significant antitumor activities (43). As such it has been the object of extensive synthetic investigation.

A number of modified amino sugar analogues have been comprehensively evaluated through the investigation of structure-activity relationship of a number of systems including: 4'-epidaunomycin (15), 4'-epiadriamycin (16), 4'-deoxydaunomycin (17), 4'-deoxyadriamycin (18), 4'-methyl derivatives, 4'-C-methylated analogues, and other configurational analogues such as L-ribo analogues, L-xylo-analogues, configurational analogues belonging to the D-series and N-acyl derivatives, N,N-dimethyl daunomycin (19) and non sugar derivatives (4c).



Scheme 1 Synthesis of (R, S) 4-Deoxydaunosamine (**44**) from 3-benzoyl-2,4-pentanedione (**48**).

The structure-activity-toxicity study revealed that 4'-deoxydaunomycin (17), 4'-epidaunomycin (15), 4'-deoxyadriamycin (18) and 4'-epiadriamycin (16) all have lower cardiotoxicity, presumably due to a lower level of superoxide produced, which was directly related to the absence of 4'-deoxy groups of these compounds, (41, 42). N,N-diacylation of daunomycin (19) seems to enhance the efficacy against test tumour cells but it was found, however, to be markedly more cardiotoxic than adriamycin (2) (44). This conclusion could be further supported by the biological antitumor activity of 3'-deamino-3'-(3-cyano-4-morpholinyl)-adriamycin (19b), which was much more active than daunomycin (1) but with extraordinarily higher cardiotoxicity (45) than that of daunomycin (1). Configurational analogues belonging to D-series, such as 7-O-(3-amino-2,3,6-trideoxy-D-arabino-hexopyranosyl)-daunomycin (19a), show weak activity (46).

The syntheses of both racemic and chiral daunosamine, 4-deoxydaunosamine and other related analogues have been reported. The idea of using 4-deoxydaunosamine was originally suggested by Wong et al., who first presented the total synthesis of (R,S) daunosamine and (R,S) 4-deoxydaunosamine from non-sugar precursors in 1975 and 1978 respectively (47, 48). Wong's synthesis of 4-deoxy-DL-daunosamine is illustrated in Scheme 1.

Oxazolono-~~α~~pyrone (41), obtained in four steps from compound (36), was hydrogenated in the presence of Adam's catalyst to a mixture of (42a) and (42b), or to only (42b), the relative stereochemistry of the products being ascertained by the analysis of the

p.m.r. spectra. Both (42a) and (42b) were converted to 3-amino-2,3,4,6-tetra-deoxy-D-threo-hexopyranose (44) by reduction of the lactone function to the hemiacetal as in (43a) and (43b), followed by hydrolysis with hydrogen bromide.

Since then, a great number of reports dealing with total syntheses of racemic daunosamine (49) and L-daunosamine have been published (50). Various efforts have been made to increase stereoselectivity in the synthetic processes.

The first total synthesis of optically active daunosamine from L-fucose was accomplished by Marsh et al (51). Various other chiral materials were also employed as precursors, such as less expensive D-sugars (52), fermentation intermediate (53), D-threonine and tartaric acid (54) and other sugar precursors (55). Sugar precursors were also used to synthesize 4-deoxydaunosamine (56). Dyong and Weiman (50) reported the first use of asymmetric induction to accomplish a chiral total synthesis of daunosamine. Other novel asymmetric synthesis (57) and the chiral pool syntheses of derivatives of daunosamine (58) were also achieved.


L-Daunosamine, prepared through asymmetric synthesis via an enantioselective intramolecular [3+2] cycloaddition of a nitron to an olefine, was reported by Peter M. Wovkulich et al. (57). Frank M. Hauser et al. carried out a stereoselective synthesis of N-trichloroacetyl derivatives of (R, S) daunosamine starting from simple acyclic precursor via a Pummerer rearrangement of the corresponding sulfoxide isomers (59). L-Daunosamine obtained from the optically

active synthetic intermediate, 7-oxa-bicyclo-[2.2.1]-hept-5-enes was reported by Pierre Vogel et al. (60), in 21.8 % overall yield.


#### 4) Methodology of Coupling Aglycones with Aminosugar Moieties

The first glycosidic coupling of daunomycinone with protected daunosamine under Koenigs-Knorr reaction was reported by Acton et al. (61). The presence of silver trifluoromethane sulfonate, which assisted glycosidation of aglycone with sugar halide, has been proved to be particularly useful for the preparation of glycosides (62). To date, almost all glycosidation processes involved in the chemical syntheses of the anthracyclines have been carried out by the classical Koenigs-Knorr reaction or modified procedure (62). The acid catalyzed condensation of an aglycone and a protected hex-1-enopyranose, such as 32, was carried out in the presence of p-toluenesulfonic acid at room temperature to give, stereoselectively, only the  $\alpha$ -glycoside (63). The high-yield enzymatic glycosidation of aklavinone (55) with corresponding sugars to give aclacinomycin A (6), was achieved by H. Umezawa and coworkers (65).

Based on these extensively fundamental studies, many new anthracycline analogues, both of natural and synthetic origin, such as 4-demethoxydaunomycin (11), 4-demethoxyadriamycin (12), 4'-deoxyadriamycin (18), 4'-deoxydaunomycin (17), 11-demethoxydaunomycin (13), 11-deoxyadriamycin (14), 4'-epiadriamycin (16), and aclacinomycin A (6), exhibit greater antitumor activity and/or less cardiotoxicity (45, 65). Some of them are being used in clinical studies.




Scheme 2 Synthesis of 1-Bromo-aminosugar (49) and aminosugar (50)




Scheme 3 Synthesis of 1-bromo-Aminosugar (49) and 1-chloro-aminosugar (50) from N-Trifluoroacetyl-daunosamine (53).


Scheme 4 Synthesis of 1-Deoxy-N,N-bis-demethyl-pyrromycin (10).




(56)

- 1) (50) or (49)
- 2) silver trifluoromethanesulfonate
- 3) dichloromethane






It was observed that removal of the 11-hydroxy function group reduces cardiotoxicity as in the cases of aclacinomycin A (6), 11-deoxydaunomycin (13) and 11-deoxyadriamycin (14) analogous. The daunomycin derivative, in which daunosamine (21) was substituted with its natural analogue rhodosamine (22), reduced mutagenicity and enhanced antitumor activity, but was markedly more cardiotoxic. It was also observed that 4'-deoxydaunosamine (29) was responsible for the increase in efficacy. In the case of 4'-deoxydaunomycin (17) and 4'-deoxyadriamycin (18) analogues, which have not been found in natural products, hence are superior to daunomycin (1) and adriamycin (2) themselves.





Therefore, it is of great interest to further investigate the structure-activity relationship of 1-deoxy-N,N-bis-demethyl-pyrromycin (10). However, based on literature survey, its physical and its preparation data were not reported before. Its biological property was only very casually mentioned as mutagenic in the *S. typhimurium* test by K. Umezawa et al. (90). It is also of great value to create

Scheme 5 Synthesis of 2-Allyl-4-hydroxy-4-methyl- $\gamma$ -butyrolacton (67).



Scheme 6 synthesis of methyl 3-N-(benzyl-carboxamido)-  
2,3,4,6-tetra-deoxy-DL-threo-hexopyranose (78)  
and its 3-epimer 80







Scheme 7 Isolation of the Anomers (82), (83), (84) and (85) from methyl 3-N-(benzyl-carboxamido)-2,3,4,6-tetra-deoxy-DL-threo-hexopyranose (78) and its 3-epimer 80

an approach for total syntheses of 78 and 80, which are the intermediates for the new aminosugars 3-N-aminomethyl-2,3,4,6-tetra-deoxy-DL-threo-hexopyranose (92) and its 3-epimer, 3-N-aminomethyl-2,3,4,6-tetra-deoxy-DL-erythro-hexopyranose (93). Compound 78 and 80 were also converted to the new amino sugars 86 and 87. These new amino sugars will be coupled with different aglycone moieties for additional study of structure-activity relationship.

The preparation of protected 1-chloro- and 1-bromo-daunosamine 50 and 49 (Scheme 2 and 3), 1-deoxy-N,N-bis-demethyl-pyrromycin (10) (Scheme 4), the new aminosugar derivatives 78 and 80 (Scheme 5-6) and new aminosugars 86 and 87 (Scheme 5-8), are described in full detail in this thesis.

Aklavinone (55), used as a precursor, for the synthesis of 10 was obtained by acidic hydrolysis of a yellow pigment which was originally isolated from the cultured broth and mycelial cake of *Streptomyces Galilaeus* var. *Siwenensis* at Sichuan Industrial Institute of Antibiotics (China) (66). Its structure was positively identified by comparing all its physical and spectroscopic data with those reported in literature (67, 68).

Glycosidation of aklavinone (55) with 1-chloro-aminosugar 50 and 1-bromo-aminosugar 49 under Koenigs-Knorr condition gave  $\alpha$ -glycoside 56 as a major product and  $\beta$  isomer 57 as the minor product. The results showed that the yield of  $\alpha$ -glycosidation with 1-chloro-aminosugar was superior to that of 1-bromo-aminosugar. The structure of 56 is unequivocally established by detailed analysis of its two dimensional p.m.r. spectrum (Fig. 5B). Basic hydrolysis of



Scheme 8 Preparation of methyl 3-N-(benzylamino-methyl)-2,3,4,6-tetra-deoxy- DL-threo-hexopyranose (86) and 3-epimer 87

56 gave the final product 10, which displays strong antitumor activity paralleling that of adriamycin and aclacinomycin A, (Table 2), (1).

The preparation of methyl 3-N-(benzyl-carboxamido)-2,3,4,6-tetradeoxy-DL-threo-hexopyranose (78) and its 3-epimer 80, are presented in part B of the experiment section. The syntheses of 78 and 80 started from diethylmalonate (63) (Scheme 5-6). Alkylation of diethylmalonate with allyl bromide followed by acidic hydrolysis and decarboxylation gave compound 66. Cyclization of 66 in the solution of hexane, p-toluenesulfonic acid and water eventually gave 2-allyl-4-methyl- $\gamma$ -butyrolactone (67) as a mixture of two diastereomers which failed to be separated from each other. Each of these diastereomers contains a pair of enantiomers which have been not resolved. The reaction of 67 with benzylamine and sodium hydride gave two diastereoisomers, 75 and 77 (Scheme 6).

Ozonolysis of 75 and 77 in anhydrous methanol followed by treatment with reducing agent trimethyl phosphite gave compounds 78 and 80, respectively (Scheme 6). Their anomeric isomers 82, 83, 84 and 85 were isolated upon column chromatography over silica, (Scheme 7), and their structures, relative stereochemistry and preferred conformations were, positively identified by detailed examination of the infrared spectra, (Figs. 14A, 15A, 17A and 18A), high resolution p.m.r. spectra (Figs. 14B, 15B, 17B and 18B) and mass spectra, (Figs. 14C, 15C, 17C and 18C), including high resolution mass spectra, (Figs. 14D, 15D, 17D, 18D).

Reduction of 78 and 80 with lithium aluminum hydride ( $\text{LiAlH}_4$ ), gave new aminosugars 86 and 87 respectively, (Scheme 8). Their four anomers, 88, 89, 90 and 91, were also isolated by preparative layer chromatography upon silica gel and HPLC.

## RESULTS AND DISCUSSIONS

### PART A: SYNTHESIS OF 1-DEOXY-N,N-BIS-DEMETHYL- PYRROMYCIN (10)

The synthesis of 1-chloro-2,3,6-trideoxy-4-O-(p-nitrobenzoyl)-3-N-trifluoroacetamido-L-lyxo-hexopyranose, [1-chloro-4-O-(p-nitrobenzoyl)-3-N-trifluoroacetyl-daunosamine] (50) was achieved by two routes.

Treatment of 3-N-trifluoroacetyl daunosamine (53) with p-nitrobenzoyl chloride in methylene chloride in presence of pyridine, gave 1,4-di-O-(p-nitrobenzoyl)-N-trifluoroacetyl daunosamine (54), as a crystalline solid, in 80 % yield. The product was further purified by recrystallization from chloroform as white crystals, m.p. = 195-197 °C, Lit. 197.0-198.5 °C, (53), (Scheme 3).

This process was developed by modification of the similar one reported by Smith et al. (70) in order to obtain an acceptable yield in small scale preparation.

Conversion of  $\beta$ -1,4-di-O-(p-nitrobenzoyl)-N-trifluoroacetyl daunosamine (54) to the very unstable 1-chloro-4-O-(p-nitrobenzoyl)-N-trifluoroacetyl daunosamine (50) was achieved by anhydrous hydrogen chloride followed by filtration to remove the insoluble p-nitrobenzoic acid. Since 50 is very moisture sensitive, the whole reaction procedure was conducted in a sealed flask under anhydrous condition.

An alternative approach, starting from methyl N-trifluoroacetyl daunosamine (45), for preparation of 1-chloro-aminosugar (50), was also explored, (Scheme 3).

Reaction of 45 with p-nitrobenzoyl chloride in a solution of methylene chloride and pyridine gave methyl 4-O-(p-nitrobenzoyl)-3-N-trifluoroacetyl-daunosamine (46) as an amorphous solid from ether, m.p. = 70-74 °C, in 96.4 % yield.

The i.r. spectrum of 46, (Fig. 3A), reveals the carbonyl stretching at 1730  $\text{cm}^{-1}$ , the aromatic C=C at 1610  $\text{cm}^{-1}$ , the  $\text{NO}_2$  bending vibration at 1530  $\text{cm}^{-1}$  and  $\text{OCH}_3$  at 2850  $\text{cm}^{-1}$ .

The further preparative layer chromatography of 46 upon silica gel gave two anomers, 47 and 48, as the syrupy compounds, (Solvent A). The compound 47 and 48 were assigned to  $\alpha$  and  $\beta$  glycoside respectively. Their p.m.r. and mass spectra are presented in Figs. 3B, 4B, 3C and 4C.

The p.m.r. spectrum of 47, Fig. 3B, shows the  $\text{C}_5\text{-CH}_3$  at 1.20 ppm as a doublet and the two methylene protons on  $\text{C}_2$  at 2.00 ppm as a multiplet. A three proton singlet at 3.40 ppm corresponds to the  $\text{C}_1\text{-OCH}_3$ . The  $\text{C}_5\text{-H}$  appears at 4.20 ppm as a quartet. The presence of a multiplet at 4.70 ppm is assigned to the  $\text{C}_3\text{-H}$ .

A one proton broad singlet at 4.95 ppm with  $W_H = 5.6$  Hz is attributed to the hydrogen on  $\text{C}_1$ . Its small coupling indicates the equatorial orientation of the anomeric hydrogen, (70).

One methine proton on  $\text{C}_4$  is at 5.45 ppm, as a barely resolved doublet. As expected, it is shifted to lower field than other methine protons in the molecule, most likely due to the desheilding effect of


the carboxyl group on C<sub>4</sub>. One proton signal at 6.37 ppm, as a broad doublet, corresponds to the NH proton. The four protons on p-nitrobenzoyl group appears at 8.28 ppm as a typical AA'BB' spin system.

In the mass spectrum of 47, Fig. 3C, loss of CH<sub>3</sub>O from the molecular ion gives the fragment M<sup>+</sup>/z 375. The fragment at M<sup>+</sup>/z 150 is due to the p-nitrobenzoyl ion.

The p.m.r. spectrum of 48, Fig. 4B, shows three methyl protons, at 1.25 ppm, as a doublet and two methylene protons on C<sub>2</sub>, at 1.85 ppm and 2.15 ppm, as two sets of a multiplet. The methoxy protons appear at 3.58 ppm as a singlet. One proton signal at 3.87 ppm as a quartet and one proton signal at 4.40 ppm as a multiplet may be assigned to the two methine protons on C<sub>5</sub> and C<sub>3</sub> respectively. The axial proton on C<sub>1</sub> occurs at 4.56 ppm as a doublet of doublets. One proton on C<sub>4</sub> is at 5.36 ppm as a poorly resolved doublet. One proton signal at 6.35 ppm, as a barely resolved doublet, corresponds to the NH. The four aromatic protons are at 8.30 ppm as the symmetric multiplet of a typical AA'BB' spin system.

The mass spectrum of 48, Fig. 4C, shows that the fragment losing one proton from the molecular ion is at M<sup>+</sup>/z 405. The fragment of the p-nitrobenzoyl ion is at M<sup>+</sup>/z 150.

Further treatment of 46 with dry hydrogen chloride in methylene chloride solution at temperature of 0°C for 4 hrs followed by evaporation of the solution to dryness gave 50, (Scheme 2), as a foamy amorphous solid from ether. The residue was dissolved in methylene chloride, evaporated to dryness. These operations was



Scheme 9 The Hydrolysis of 7-O-3'-N-(Trifluoroacetyl)-4'-O-(p-nitrobenzoyl)- $\alpha$ -daunosaminyl-aklavinone **(56)** under Acidic Condition.

repeated once more until the residue was free of hydrogen chloride. It is a precaution against possible cleavage of the glycosidic bond under acidic condition, (Scheme 9). This residue was permitted to couple with aklavinone without further purification.

Aklavinone (55) was obtained by acidic hydrolysis of a yellow amorphous solid, which exhibited potent antitumor activity, (66). This solid was separated from the cultured broth and mycelial cakes of *Streptomyces Galilaeus* var. *Siwenensis*. This amorphous solid was further purified by preparative layer chromatography upon silica gel (Solvent A) and recrystallized from chloroform. The purified yellow crystal shows that its physical and spectroscopic properties are parallel those of Aclacinomycin A, reported by H. Umezawa et al. (71).

The purified yellow pigment was hydrolyzed with 0.3 M sulfuric acid to give orange crystalline needles, after recrystallization from chloroform. This orange material was identified as aklavinone (55) by comparing its physical and spectroscopic data with those reported in literature (67, 68), and further confirmed by the high resolution p.m.r. spectrum which was not available in literature (Fig. 1B-1).

In the p.m.r. spectrum of 55, Fig. 1B-1, shows the small coupling between the proton on C<sub>7</sub>, at 2.35 ppm and the two protons on C<sub>8</sub>, at 2.45 ppm and the long range coupling between C<sub>8</sub>-H<sub>e</sub> and C<sub>10</sub>-H<sub>e</sub> of 55 based on an expanded p.m.r. spectrum.

Double irradiation studies (Fig. 1B-2) further revealed the relationship among C<sub>7</sub>-H<sub>e</sub>, C<sub>8</sub>-H<sub>a</sub>H<sub>e</sub> and C<sub>10</sub>-H. When frequency sweep double irradiation was applied at 5.38 ppm, corresponding to

the  $H_7-H_e$ , spectral simplification due to the decoupling of  $C_8-H_aH_e$  from the  $C_7-H_e$  was observed. Decoupling of the proton of the  $C_8-H_e$  from the  $C_{10}-H_e$  was also observed by the double irradiation on the  $C_{10}-H_e$  at 4.13 ppm.

This operation converts the original broad doublet at 2.10 ppm, corresponding to the  $C_8-H_a$ , to a fairly sharp doublet which clearly indicates the decoupling from the  $C_{10}-H_e$ . All these p.m.r. spectroscopic data can only be accommodated to the half chair form of the preferred conformation of D ring as shown in Fig. 2.




Fig. 2 The Half-Chair Conformation of D ring of Aklavinone (55)

Thus these spectroscopic features readily distinguished aklavinone from other epimers, e.g. aklavinone I and aklavinone II which may also be isolated from the culture medium, (67).

The reaction of aklavinone (55) with 50 in the presence of silver trifluoromethane sulfonate, followed by preparative layer chromatog-


raphy upon silica gel, gave 7-O-4'-O-(p-nitrobenzoyl)-3'-N-trifluoroacetyl- $\alpha$ -daunosaminy-l-aklavinone (56) as predominant product in 40 % yield, and a small amount of the  $\beta$ -isomer (57).

Introducing the 4-O-p-nitrobenzoyl group in a sugar moiety for improving stereoselectivity of coupling reaction under Koenigs-Knorr conditions, was reported by Dejten-Juszyuski, (73, 74).


Thus it is assumed that the high stereoselectivity of the Koenigs-Knorr reaction of 50 and 49 with aklavinone (55) is attributed to the presence of the p-nitrobenzoyl group at C-4. The p-nitrobenzoyl group most likely participates in this reaction to form stable 7-membered ring nitrobenzoyloxonium intermediate (59). This intermediate probably facilitates the axial attack by the hydroxyl group in the formation of  $\alpha$ -anomeric compound (56), as illustrated in Scheme 10, (74).

Acton et al. (75) obtained the glycoside with more stereoselectivity with 4-O-p-nitrobenzoyl-3-N-trifluoroacetyl-daunosaminy-l bromide over the chloro sugar. However our experiment results shows that 1-chloro-aminosugar (50) seems to be superior to 1-bromo-aminosugar (49) in coupling with aklavinone (55) to give  $\alpha$ -isomer (56) in 40.0 % yield, as opposed to the 26.9 % yield obtained from 1-bromo-aminosugar. These results parallel those contributed by Acarmone et al. in the preparation of analogues of adriamycin and daunomycin (76). The phenomenon may be well explained by the HSAB principle (77).


According to the HSAB principle, the C<sub>1</sub> in 49 is a less hard acidic centre than that in 50. Consequently the carbonyl oxygen,



aklavinone (55)





aklavinone I (55a)




akavinone II (55b)

Scheme 10 Highly Stereoselective Glycosidation of Aklavinone (55)  
with Aminosugar (49) and (50)



R<sub>3</sub> =



which is considered as a hard base, prefers to attack the harder acidic centre at the C<sub>1</sub> of 1-chloro-aminosugar to form 7-membered nitrobenzoyloxonium intermediate (59). Therefore the choice of 1-chloro-aminosugar (50) may provide a more stereoselective approach to give the  $\alpha$ -glycoside (56) in the higher yield than that of 1-bromo-aminosugar (49).

The stereochemistry of both 56 and 57 are positively established by detailed analysis of their two dimensional p.m.r. spectrum (Fig. 5B), <sup>13</sup>C n.m.r. spectrum (Fig. 5D) and high resolution p.m.r., (Figs. 6B).

The i.r. spectrum of 56, Fig. 5A, shows the OH stretching absorption (non hydrogen bonding) at 3530 cm<sup>-1</sup>. The NH stretching is at 3430 cm<sup>-1</sup> and chelated phenolic OH is at 3500-3000 cm<sup>-1</sup>. The carbonyl stretching absorptions of -COOCH<sub>3</sub>, PhCOO, and NHCOCF<sub>3</sub> occur at 1735 cm<sup>-1</sup> as a broad and intense band due to overlapping with each other. The quinone carbonyl stretching appears at 1680 cm<sup>-1</sup> and the chelated carbonyl stretching is at 1630 cm<sup>-1</sup>. The aromatic C=C stretching and the NO<sub>2</sub> absorption are at 1620 cm<sup>-1</sup> and 1535 cm<sup>-1</sup> respectively.

The two dimensional p.m.r. spectrum of 56, Fig. 5B, shows one proton singlet at 5.64 ppm with W<sub>H</sub> = 6 Hz, assignable to the equatorial hydrogen on C'<sub>1</sub>, whereas the proton on C'<sub>1</sub> of 57 (Fig. 6B) is assigned to the axial orientation on the basis of one proton signal at 5.35 ppm, as a quintet, with W<sub>H</sub> = 13 Hz, (76).

In the compound 56, the three proton triplet at 1.11 ppm with J = 6.2 Hz corresponds to the C<sub>13</sub>-CH<sub>3</sub>. Three methyl protons (C<sub>5</sub>-

CH<sub>3</sub>) are at  $J = 1.26$  ppm as a doublet with  $J = 7.0$  Hz due to the coupling with C'<sub>5</sub>-H.

Two chemically and magnetically non equivalent protons on C<sub>13</sub> occur at 1.54 ppm and 1.79 ppm as the AB part of an ABC<sub>3</sub> spin system due to the influence of the adjacent chiral centre (C<sub>9</sub>).

The two methylene protons (C'<sub>2</sub>-H<sub>a</sub>H<sub>e</sub>) appear at 2.10 ppm as a multiplet as the AB part of an ABXY system. This conclusion is supported by the analysis of the two dimension spectrum (Fig. 5B) which shows C'<sub>2</sub>-H<sub>a</sub>H<sub>e</sub> coupling with C'<sub>1</sub>-H at 5.70 ppm and C'<sub>3</sub>-H at 4.46 ppm. The C<sub>8</sub>-H<sub>a</sub> is at 2.34 ppm as a broad doublet with  $J_{8a8e} = 15$  Hz and  $J_{8a7e} = 1$  Hz. The C<sub>8</sub>-H<sub>e</sub> appears at 2.62 ppm as a doublet of doublet with  $J_{8a8e} = 15$  Hz and  $J_{7e8e} = 5$  Hz. The two dimensional spectrum indicates the coupling of H<sub>8a</sub> with H<sub>8e</sub> and both coupling with H<sub>7e</sub>. The small coupling of  $J_{8a7e}$  is due to the proton of C<sub>9</sub>-OH forming a hydrogen bond with the oxygen of C<sub>7</sub>-O-sugar; consequently the half chair form of the D ring is slightly twisted expanding the H<sub>8a</sub>-C<sub>8</sub>-C<sub>7</sub>-H<sub>7e</sub> dihedral angle to about 75°, (15, 24).

The three protons of C<sub>10</sub>-COOCH<sub>3</sub> appear at 3.70 ppm as a singlet. A broad singlet at 3.84 ppm, which exchanges with deuterium, is assigned to the C<sub>9</sub>-OH. The two dimensional spectrum also reveals the coupling of C<sub>9</sub>-OH with C<sub>10</sub>-H. One proton singlet at 4.15 ppm is assigned to the C<sub>10</sub>-H<sub>e</sub>. This signal, in an expanded spectrum, reveals broadening which indicates the presence of a weak long range coupling. This assumption is also clearly verified by the two dimensional spectrum, which indicates the hydrogen on C<sub>10</sub> (H<sub>e</sub>)

W-type long-range coupling with the C<sub>8</sub>-H<sub>e</sub>. Thus the coupling phenomenon is in agreement with the conformation of the D ring, in which the hydroxy groups on C<sub>7</sub> and C<sub>9</sub> have a relationship of the quasi-diaxial cis orientation, and the C<sub>10</sub>-COOCH<sub>3</sub> group has a quasi-axial orientation in cis position to the C<sub>9</sub>-CH<sub>2</sub>CH<sub>3</sub>.

The C'<sub>3</sub>-H<sub>a</sub> overlaps C'<sub>5</sub>-H<sub>a</sub> at 4.47 ppm and the two dimensional p.m.r. clearly shows that the C'<sub>3</sub>-H<sub>a</sub> is coupled to both the C'<sub>2</sub>-H<sub>a</sub>H<sub>e</sub> which appear at 2.10 ppm as a multiplet due to its weak coupling to the C'<sub>4</sub>-H<sub>e</sub>. The C'<sub>5</sub>-H<sub>a</sub> appears only as a quartet with  $J_{CH_3, 5a} = 6$  Hz. The C'<sub>4</sub>-H<sub>e</sub> is observed at 5.47 ppm as a broad singlet.

The signal of C<sub>7</sub>-H<sub>e</sub> occurs at 5.38 ppm as a broad singlet; a result of a weak coupling to both the C<sub>8</sub>-H<sub>a</sub> and C<sub>8</sub>-H<sub>e</sub>. One proton signal which appears at the lowest field, 5.70 ppm, among the methine protons, is assignable to the C'<sub>1</sub>-H<sub>e</sub>, (76). The NH at 6.20 ppm appears as a broad doublet as a consequence of fast exchange of the N-H proton (78), restricted rotation of the trifluoroacetamide function and quadropole relaxation of the nitrogen (79). The aromatic proton on C<sub>11</sub> is at 7.73 ppm as a singlet with a small coupling with the C<sub>10</sub>-H<sub>e</sub>. The C<sub>3</sub>-H is at 7.33 ppm with  $J_{2, 3} = 8$  Hz and 7.85 ppm with  $J_{1, 3} = 1$  Hz due to coupling with the C<sub>2</sub>-H and the C<sub>1</sub>-H respectively. The C<sub>2</sub>-H, which appears at 7.72 ppm as a triplet, is recognised as the coupling with the C<sub>1</sub>-H and C<sub>3</sub>-H. The typical AA'BB' pattern at 8.33 ppm is assigned to the four aromatic protons. Two phenolic proton signals in the lowest field at 12.00 ppm and 12.78 ppm corresponds to C<sub>4</sub>-OH and C<sub>6</sub>-OH respectively.

The structure of 56 was further confirmed by  $^{13}\text{C}$  n.m.r. spectrum (Fig. 5D). The assignments of the carbons were listed in Table 1-1 and Table 1-2, (80). The FAB mass spectrum (1) of 56 shows the molecular ion at  $M^+ = 786$ .


Removal of the protecting groups was achieved by the treatment of 56 in a mixture of tetrahydrofuran, methanol, potassium carbonate solution while stirring at mild temperature. Then the reaction solution was adjusted to pH 9 with dilute hydrochloric acid and usual workup afforded a dark orange residue. This compound was subjected to preparative layer chromatography upon silica gel to give an amorphous solid (10) in 37.9% yield, m.p. = 132-143 °C (decomposed).

The concentration of base and time for the hydrolysis are crucial factors. Under stronger basic conditions, and longer reaction time, many other side products were observed, which might be caused by the cleavage of ester bond and glycosidic bond of the glycoside. One of these by-products was identified as compound 55a. (Scheme 11).

The i.r. spectrum of 10 (1) shows the OH stretching at  $3600\text{ cm}^{-1}$  and  $3520\text{ cm}^{-1}$ . The primary  $\text{NH}_2$  stretching is at  $3470\text{ cm}^{-1}$  and  $3430\text{ cm}^{-1}$ . The chelated OH stretching absorbs at  $3500\text{--}3100\text{ cm}^{-1}$ . The quinone carbonyl stretching of  $\text{COOCH}_3$  appears at  $1735\text{ cm}^{-1}$  and the carbonyl stretching absorption is at  $1680\text{ cm}^{-1}$ . The chelated carbonyl stretching is at  $1580\text{ cm}^{-1}$ .

The tumour cell growth inhibition assay of 10 shows its significant antitumor activity comparable with Adriamycin (2) and Aclacinomycin A (6) (Table 2).

Table 1-1 Interpretation of  $^{13}\text{C}$  N. m. r. Spectrum of 7-O-3'-N-(Trifluoroacetyl)-4'-O-(p-nitrobenzoyl)- $\alpha$ -daunosaminyl-aklavinone (56), (Fig. 5D), (80).




| ppm   | Assignment     | ppm   | Assignment      |
|-------|----------------|-------|-----------------|
| 125.0 | C <sub>1</sub> | 131.0 | C <sub>20</sub> |
| 126.0 | C <sub>2</sub> | 143.0 | C <sub>21</sub> |
| 121.0 | C <sub>3</sub> | 135.0 | C <sub>22</sub> |
| 157.5 | C <sub>4</sub> | 101.0 | C' <sub>1</sub> |
| 192.0 | C <sub>5</sub> | 30.0  | C' <sub>1</sub> |
| 157.0 | C <sub>6</sub> | 58.0  | C' <sub>3</sub> |
| 67.0  | C <sub>7</sub> | 72.5  | C' <sub>4</sub> |
| 32.0  | C <sub>8</sub> | 72.0  | C' <sub>5</sub> |
| 73.0  | C <sub>9</sub> | 17.0  | C' <sub>6</sub> |

Table 1 -2.

---

| ppm   | Assignment      | ppm   | Assignment       |
|-------|-----------------|-------|------------------|
| 47.0  | C <sub>10</sub> | 171.0 | C' <sub>7</sub>  |
| 122.0 | C <sub>11</sub> | 115.0 |                  |
| 181.0 | C <sub>12</sub> | 116.0 | C' <sub>8</sub>  |
| 35.0  | C <sub>13</sub> | 117.0 |                  |
| 14.0  | C <sub>14</sub> | 118.0 |                  |
| 165.0 | C <sub>15</sub> | 161.5 | C' <sub>9</sub>  |
| 53.0  | C <sub>16</sub> | 161.0 | C'' <sub>1</sub> |
| 134.0 | C <sub>17</sub> | 138.0 | C'' <sub>2</sub> |
| 131.5 | C <sub>18</sub> | 132.0 | C'' <sub>3</sub> |
| 133.5 | C <sub>19</sub> | 152.0 | C'' <sub>4</sub> |

---



Scheme 11 The Hydrolysis of 1-Deoxy-N,N-bis-demethylpyrromycin (10) under Strong Basic Conditions

Table 2. ID<sub>50</sub> values of Adriamycin (2), Aclacinomycin A (6) and compound 10 (1).

|                              | P388/S               | P388/A1              |
|------------------------------|----------------------|----------------------|
| Adriamycin ( <u>2</u> )      | $6 \times 10^{-8}$ M | $3 \times 10^{-6}$ M |
| Aclacinomycin A ( <u>6</u> ) | $7 \times 10^{-7}$ M | $6 \times 10^{-6}$ M |
| Compound <u>10</u>           | $3 \times 10^{-7}$ M | $5 \times 10^{-6}$ M |

## RESULTS AND DISCUSSIONS

### PART B: SYNTHESIS OF METHYL 3-N-(BENZYL-CARBOXAMIDO)-

#### 2,3,4,6-TETRADEOXY-DL-THREO-HEXOPYRANOSE (78)

#### AND ITS 3-EPIMER (80)


Compounds methyl 3-N-(benzyl-carboxamido)-2,3,4,6-tetra-deoxy-DL-threo-hexopyranose (78) and its 3-epimer 80, which are considered as intermediates for the total syntheses of novel aminosugars, 3-aminomethyl-2,3,4,6-tetra-deoxy-DL-threo-hexopyranose (92) and 3-aminomethyl-2,3,4,6-tetra-deoxy-DL-erythro-hexopyranose (93), are prepared in the acceptable overall yield starting from diethylmalonate (63). Compound 78 and 80 were also converted to new aminosugars, e.g. methyl 3-N-(benzylamino-methyl)-2,3,4,6-tetra-deoxy-DL-threo-hexopyranose (86) and methyl 3-N-(benzylamino-methyl)-2,3,4,6-tetra-deoxy-DL-erythro-hexopyranose (87).

The carbanion of diethylmalonate (63), which was generated by treatment of ethylmalonate with finely ground potassium carbonate in acetone, reacted with allyl bromide to give 2,2-diallyl diethylmalonate (64) as a colorless liquid after distillation under reduced pressure at 87-89 °C/1.5 mm in 95% yield.

Predictably, introduction of a second allyl group was more difficult than that of the first one, since the first allyl group introduced was considered as an electron donating group which could decrease acidity of hydrogen to the carbonyl group. In addition, steric hindrance of the first group could also cause difficulty for

further alkylation. Consequently, high temperature and relatively long reaction time were required for completion of the reaction. Monitoring reaction process by t.l.c. revealed the concurrent consumption of the starting material (63) ( $R_f = 0.3$ ) and the formation of a monoalkylated intermediate (63a), ( $R_f = 0.5$ ), and final product (64), ( $R_f = 0.65$ ), (Solvent G).

The infrared spectrum of 64, Fig. 8A, shows the intense carbonyl stretching vibration at  $1720\text{ cm}^{-1}$ , the weak absorption of the C=C stretching vibration at  $1640\text{ cm}^{-1}$ , and the C-O-C bending vibration at  $1200\text{ cm}^{-1}$ , as a broad band.



In the p.m.r. spectrum of 64, (Fig. 8B), the six protons of two methyl groups in two chemically equivalent ethyl groups absorb at 1.32 ppm as a triplet. The four methylene protons in the two ethyl groups appears at 4.17 ppm as a quartet due to the coupling with methyl protons as an A<sub>2</sub>X<sub>3</sub> spin system. The six olefinic protons in the two equivalent allyl groups absorb at 4.86-6.00 ppm as an ABX spin system. The absorption at 5.18 ppm as a broad singlet was

assigned to the olefinic proton in trans position to the proton on the same carbon with the alkyl side chain ( $H_{\text{trans}}$ ) and the absorption at 5.00 ppm as a broad singlet belongs to the proton in cis position to the hydrogen on the same carbon with the alkyl side chain ( $H_{\text{cis}}$ ). A multiplet at 5.35-6.00 ppm in a low field is assignable to the olefinic proton on the same carbon with the alkyl proton ( $H_{\text{gem}}$ ). The four allylic protons absorb at 2.55 ppm as a broad doublet due to their coupling with the adjacent  $H_{\text{gem}}$  and long range coupling with the  $H_{\text{trans}}$  and  $H_{\text{cis}}$ .

2,2-diallyl-diethylethylmalonate (64) was hydrolyzed in a solution of potassium hydroxide (KOH), methanol and water under reflux followed by adding concentrate hydrochloric acid at low temperature ( $0^{\circ}\text{C}$ ) to neutralize the solution to pH 6-7 to gave corresponding 2,2-diallyl-malonic acid (65) in 91% yield, as a white crystalline product after recrystallization from chloroform. m.p. =  $126-128^{\circ}\text{C}$ . During the neutralization, if the local concentration of the acid in the solution was high and the solution was stirred under room temperature, unidentified by-products could be detectable by t.l.c.. This is probably caused by polymerization and/or decarboxylation.

The i.r. spectrum and p.m.r. spectrum of 65 are presented in Figs. 9A and 9B respectively. The i.r. spectrum shows the OH stretching vibration at  $3550\text{ cm}^{-1}$  due to non hydrogen bonding monomer. The OH stretching absorption of a dimer occurs at  $3500-3000\text{ cm}^{-1}$ .

The carbonyl stretching absorption of a monomer is at  $1760\text{ cm}^{-1}$  and the carbonyl absorption of a dimer appears in lower frequency at  $1710\text{ cm}^{-1}$  due to intermolecular hydrogen bonding, (81). The C=C

absorbs at  $1650\text{ cm}^{-1}$  as a weak band. As expected, the strong broad band at  $1200\text{ cm}^{-1}$  corresponding to C-O-C bending vibration of the ester was nonapparent compared to the spectrum of 64, (Fig. 8A).

In the p.m.r. spectrum of compound 65, (Fig. 9B), the four allylic protons appear at 2.71 ppm as a doublet. The two equivalent olefinic protons ( $H_{\text{gem}}$ ), in Fig. 5, are at 5.70 ppm as a multiplet. The two proton signal at 5.16 ppm, as a poorly resolved sextet, corresponds to the two olefinic protons ( $H_{\text{cis}}$ ). The two protons ( $H_{\text{trans}}$ ) appear at 5.22 ppm as a poorly resolved doublet. There are no signals at a lower field for the two hydroxyl protons probably due to the fast exchange of these protons.

In the mass spectrum of 65, (Fig. 9C),  $M^+/z$  185 is visualized as a  $M+1$  species in which the molecular ion may abstract one proton from the neutral molecule in the intermolecular process.  $M^+/z$  166 is recognized as arising by the loss of  $H_2O$  from the molecular ion. The formation of the ion  $M^+/z$  125 is due to the sequential loss of  $H_2O$ . The formation of the basic fragment ion  $M^+/z$  79 presumably results from the sequential loss of  $H_2O$ ,  $CO_2$  and  $CO$  molecules from ion  $M^+/z$  185 ( $M+1$ ). These fragment patterns were confirmed by high resolution mass spectrum.


The decarboxylation of 65 proceeded at about  $80^\circ\text{C}$  in a solution of acetic acid, water and *N,N*-dimethyl formamide (DMF) with the evolution of carbon dioxide. This eventually led to 66 as a colorless liquid in 95% yield after distillation under reduced pressure at  $98\text{-}100^\circ\text{C} / 2.5\text{ mm}$ .

The infrared spectrum of 66, Fig. 10A, shows similarity with that of 65 in the region of carbonyl stretching absorption. But the carbonyl absorptions of monomer and dimer are shifted to frequency lower than those of 66 at  $1742\text{ cm}^{-1}$  and  $1702\text{ cm}^{-1}$  respectively. The OH stretching of the monomer absorbs at  $3500\text{ cm}^{-1}$  and OH stretching of dimer is at a region of  $3500\text{-}3000\text{ cm}^{-1}$ . The much more intense absorption of C=C is observed at  $1650\text{ cm}^{-1}$  compared to that of compound 65 at  $1640\text{ cm}^{-1}$ , (Fig. 9A). This is probably because of the diminishment of interplay of dipole-dipole interaction of the two carbonyl groups in 65 which tends to suppress bond polarization, (82).


The p.m.r. spectrum of 66, Fig. 10B, shows the four allylic protons at 2.37 ppm as a broad doublet indicating their small coupling with the  $H_{\text{gem}}$  and the long range coupling with the  $H_{\text{trans}}$  and  $H_{\text{cis}}$ . The absorptions of the six olefinic protons in the two chemically equivalent allyl groups occur at 4.96 ppm ( $H_{\text{cis}}$ ), 5.20 ppm ( $H_{\text{trans}}$ ), and 5.83 ppm ( $H_{\text{gem}}$ ) as an ABX spin system. The carboxylic proton occurs at a lower field, at 11.5 ppm, as a singlet.

In the mass spectrum of 66, (Fig. 10C), the molecular ion appears at  $M^+/z$  140. The loss of  $-\text{COOH}$  from the molecular ion presumably gives the fragment  $M^+/z$  95. The formation of fragment  $M^+/z$  99 probably comes from the allylic fission of the molecular ion by the loss of  $\text{CH}_3\text{-CH=CH}_2$ . The basic ion occurs at  $M^+/z$  43.


Cyclization of 66 in a solution of hexane, p-toluenesulfonic acid




threo (68)  
(2R,4R)



threo (69)  
(2S,4S)



erythro (70)  
(2R,4S)




erythro (71)  
(2S,4R)


and proper amount of water under hexane-water azeotrope afforded 67 as a colorless liquid after distillation under reduced pressure at 87-90 °C/2.6 mm. The yield was 56.3 %.

The presence of certain amounts of water was a crucial factor for the formation of the  $\delta$ -butyrolactone (67). In the absence of water the reaction gave, predominantly, high boiling by-product which was not characterized. It was suggested that water may prevent the formation of carbonium ion (72) which could inevitably undergo intramolecular and intermolecular nucleophilic reaction to give the undesirable by-product. In addition, the yield of the reaction was significantly improved by choosing hexane as a solvent over benzene. Because benzene ring could be attacked by the carbonium ion (73) under acidic conditions through a Friedel-Crafts like reaction mechanism to give the by-product.

The presumable mechanism of the reaction was elucidated in Scheme 12. In the presence of water, the reaction would favour the formation of  $\delta$ -butyrolactone (67), even through water may cause the ring opening to give the carboxylic acid (74) in the meantime. Removal of water by hexane water azeotrope could eventually reverse the reaction to reform the  $\gamma$ -butyrolactone (67). Consequently, the intramolecular attack of the hydroxy group of 66 on either carbonium ion (73), created by protonation of two equivalent olefines in acidic condition, gave 67 as a mixture of two diastereoisomers. Each of these diastereomers contains a pair of enantiomers, e.g. threo isomer (2R,4S) 68 or (2S,4R) 69; and erythro isomer (2S,4S) 70 or (2R,4R) 71. The attempts to separate one




Scheme 12 Formation of 2-Allyl-4-hydroxy-4-methyl- $\gamma$ -butyrolactone (67) by Cyclization of 2-Allyl-4-pentenoic acid (66).



Scheme 13 Possible Pathways for Formation of the Fragments in the Mass Spectrum of 2-Allyl-4-hydroxyl-4-methyl- $\gamma$ -butyrolactone (67).

diastereoisomer from the other failed. Their existence are only verified by the p.m.r. spectrum of 67, (Fig. 11B), which shows that the ratio of two diastereoisomers is about 2:1. The threo isomer is probably a major product since it is more thermodynamically stable than that of erythro isomer due to its less steric interaction between the allyl group and the methyl group, (83).

The i.r. spectrum of 67, Fig. 11A, shows the carbonyl stretching absorption at  $1762\text{ cm}^{-1}$  as a strong sharp band and a weak C=C stretching absorption at  $1640\text{ cm}^{-1}$ . The C-O-C asymmetric stretching absorbs at  $1180\text{ cm}^{-1}$  as a strong sharp band.



(67)

The p.m.r. spectrum of 67, Fig. 11B, indicates three methyl protons at 1.38 ppm as a doublet. The three proton signal at 1.28 ppm is probably due to another diastereoisomer. The two allylic protons, the one methine proton on C<sub>2</sub>, and the two methylene protons on C<sub>3</sub>, occur at 2.00-3.00 ppm, as a multiplet. The one methine proton appears at 4.50 ppm as a sextet and the three olefinic protons is observed at 5.00-6.20 ppm as an ABX spin


system. The chemical shift of these protons are coincident except the methyl protons of the two diastereoisomers.

The mass spectrum of 67, Fig. 11C, shows the molecular ion at  $M^+/z = 140$  which is further proved by the high resolution mass spectrum (Fig. 11D). The basic fragment ion at  $M^+/z = 81$ , is due to the loss of both carbon dioxide and the methyl group. The loss of carbon dioxide probably gives the peak  $M^+/z = 96$ . The fragment  $M^+/z 125$  is visualized as raising by loss of the methyl group. The presumed fragment patterns are elucidated in Scheme 13.

Compound 67, as a mixture of the two diastereoisomers, was allowed to react with benzylamine and sodium hydride at  $50^\circ\text{C}$  to afford a brown-yellow syrup. This syrup contained almost an equal amount of the two diastereoisomers visualized by t.l.c. The syrup was subjected to column chromatography over silica (Solvent I) to give, in order of elution, 75 as a slight yellow syrup in 19.5% yield and 77 as white crystals in 25% yield, after solvent evaporation. The recrystallization of 77, from a solution of ether and chloroform (10:1, v/v), gave a white crystalline solid as small needles, with m. p =  $69-70^\circ\text{C}$ .

The i.r. spectrum and the p.m.r. spectrum of 75 and 77 are presented in Fig. 12A, 12B and 13A, 13B respectively. These molecules do not have one simple preferable conformation, but are, in general, a mixture of various conformers. As a result, the chemical shifts and the coupling constant obtained from the spectrum are the weighted averages of each conformer. However their relative stereochemistry could be finally induced from analysis


Scheme 14 The Epimerization of (R,S) 2-Allyl-4-hydroxyl-4-methyl-erythro- $\gamma$ -butyrolacton (70)



of the p.m.r. spectra of their corresponding cyclization products 82, 83 and 84, 85 obtained in the next step.

The same equivalents of benzylamine and sodium hydride were required to react with 68. Excess benzylamine and sodium hydride led to give more of 77 and less of 75 as judged by t.l.c.. The ratio of the two diastereoisomers remained unchanged by reducing the temperature to about 35 °C.

It is assumed that an excess of benzylamine anion would cause the epimerization of erythro 70 to give a more thermally stable threo isomer 69 through enolisation by losing hydrogen atom to the carbonyl group. The isomer 69 is eventually attacked by benzylamido anion to afford 77, as a major compound, (Scheme 14). The ratio of 77 ( $R_f = 0.5$ ) and 75 ( $R_f = 0.6$ ) is about 5:1 as judged by t.l.c., (Solvent A). The infrared and p.m.r. spectra of 75 are presented in Fig. 12A and 12B.



The i.r. spectrum of 75 shows the stretching absorption of free hydrogen bonding OH at 3580  $\text{cm}^{-1}$  and the NH stretching absorption at 3420  $\text{cm}^{-1}$ . The stretching absorption of hydrogen

bonding OH is evident at  $3320\text{ cm}^{-1}$  as a broad band. The stretching vibration of  $-\text{CO}-\text{NH}-$ , as a broad band, is at  $1670\text{ cm}^{-1}$ . The  $\text{C}=\text{C}$  stretching vibration absorbs at  $1620\text{ cm}^{-1}$  as a shoulder and the  $\text{HN}-\text{C}$  bending vibration and amide II band are present at  $1520\text{ cm}^{-1}$ .

In the p.m.r. spectrum of 75, Fig. 12B, the three methyl protons on  $\text{C}_5$  are at 1.19 ppm, as a doublet with  $J = 6.2\text{ Hz}$ , due to vicinic coupling with one methine proton on  $\text{C}_4$ . The two allylic protons are both magnetically and chemically non-equivalent due to the influence of the adjacent chiral centre on  $\text{C}_2$  and can be differentiated from the two methylene protons on  $\text{C}_3$  by Shooley equation, (84). Consequently, these protons occur at 1.57 and 1.80 ppm, as two sets of a doublet of triplets, as the AB pattern of an ABCD spin system. The hydroxyl proton appears at 1.97 ppm as a doublet with  $J = 4.5\text{ Hz}$  due to coupling with the adjacent methine proton on the  $\text{C}_4$ , while in the spectrum of 77, the OH absorption is at 2.10 ppm as a broad singlet. One methine proton on  $\text{C}_2$ , adjacent to the carbonyl group, appears at 2.20 ppm as a multiplet. The two methylene protons on  $\text{C}_3$  are at 2.45 ppm, as a multiplet, as the AB pattern of an ABCD spin system. One methine proton on  $\text{C}_4$  appears at 3.85 ppm as a multiplet. The two benzylic protons, which are magnetically and chemically non-equivalent because of their diastereotopic characters, absorb at 4.45 ppm, as a doublet of quartets of the typical AB pattern with  $J_{\text{gem}} = 15\text{ Hz}$  and  $J_{\text{CH}_3, \text{NH}} = 6\text{ Hz}$ . The two terminal olefinic protons absorb at 5.10 ppm as a broad singlet ( $\text{H}_{\text{trans}}$ ) and 5.03 ppm as a broad doublet ( $\text{H}_{\text{cis}}$ ). One olefinic proton ( $\text{H}_{\text{gem}}$ ) occurs at 5.750 ppm as a multiplet in lower

field. These experimental data are in good agreement with the values, 4.97 ppm ( $H_{cis}$ ), 5.03 ppm ( $H_{trans}$ ), and 5.70 ppm ( $H_{gem}$ ) calculated by an equation which is derived from an empirical correlation based on an compilation of experimental data, (85). The NH is at 6.00 ppm, as a broad singlet, and the five aromatic protons are observed at 7.30 ppm as a multiplet.

The mass spectrum of 75, (Fig. 12C), shows the molecular ion at  $M^+/z$  247 and a basic peak corresponding to the tropylium ion at  $M^+/z$  91. The loss of  $H_2O$  from the molecular ion probably gives the fragment ion  $M^+/z$  229. The formation of the fragment ion  $M^+/z$  189 (M-58) presumably came from the McLaffery rearrangement of the molecular ion. The fragment ion at  $M^+/z$  202 is more likely attributable to the loss of  $CH_3CHOH$  by the cleavage of the molecular ion.

The i.r. spectrum and p.m.r. spectrum of 77 are presented in Fig. 13A and 13B. As expected, the i.r. spectrum is similar in character to that of 75 except for the weaker absorption at  $3320\text{ cm}^{-1}$ , corresponding to intermolecular hydrogen bonding, and the minor difference at the finger print region when compared to the spectrum of 75. The free hydrogen bonding OH appears at  $3580\text{ cm}^{-1}$  and the NH stretching absorption occurs at  $3430\text{ cm}^{-1}$ . The carbonyl stretching absorption appears at  $1670\text{ cm}^{-1}$  as a broad band and the C=C stretching appears at  $1640\text{ cm}^{-1}$  as a shoulder (medium). The amide II band and the aromatic skeleton absorption are overlapped as a broad singlet at  $1520\text{ cm}^{-1}$ .

The p.m.r. spectrum shows of 77 the three methyl protons on C<sub>4</sub>, at 1.19 ppm, as a doublet with J = 6.2 Hz. The two allylic protons are observed at 1.60 ppm and 1.85 ppm as a quintet and a doublet of triplets as the AB part of an ABCD spin system. One broad singlet, at 2.08 ppm, is due to the hydroxyl group on C<sub>4</sub>. The one methine proton on C<sub>2</sub>, adjacent to the carbonyl functional group, appears at 2.25 ppm as a multiplet and two methylene protons on C<sub>3</sub> absorb at 2.35 ppm as a multiplet. The methine proton on C<sub>4</sub> occurs at 3.85 ppm as a multiplet. As expected, two magnetically and chemically non-equivalent benzylic protons are present, at 4.50 ppm, as a doublet of quartets of a typical AB spin system. Two proton signals; one at 5.10 ppm as a broad singlet, and the other at 5.03 ppm as a broad doublet, are assignable to the terminal olefinic proton H<sub>trans</sub> and H<sub>cis</sub> respectively. One olefinic proton (H<sub>gem</sub>) is a multiplet at 5.75 ppm. The NH absorbs at 6.00 ppm as a broad singlet and the five aromatic protons are at 7.73 ppm as a multiplet.

The mass spectrum of 77, (Fig. 13C), shows the molecular ion at M<sup>+</sup>/z 247. The loss of water from the molecular ion forms a fragment ion M<sup>+</sup>/z 229 (M-H<sub>2</sub>O). The fragment ion M<sup>+</sup>/z 189 is obviously attributed to a McLafferty rearrangement of the molecular ion by the subsequent loss of neutral molecule CH<sub>3</sub>COH=CH<sub>2</sub>. The formation of the fragment ion M<sup>+</sup>/z 106 (NH-CH<sub>2</sub>-Ph) was recognized as the raising by cleavage of the molecular ion. A tropylium ion appears at M<sup>+</sup>/z 91 as a basic peak due to benzylic fission (Scheme 15).


Ozonolysis of 75 in absolute methanol at  $-20^{\circ}$  to  $-25^{\circ}$  C, followed by the treatment with trimethyl phosphite under reflux, gave a slight brown syrupy residue. It was subjected to column chromatography over silica (Solvent M) to give, in order of elution, a white amorphous solid (78) as the mixed acetals in 74% yield, and a minor amount of 79. Compound 78 could be further purified by recrystallization from ether and petroleum to give white amorphous solids, m.p. =  $94-95^{\circ}$  C. Compound 79 was recrystallized from methylene chloride as white crystals, m.p. =  $155-157^{\circ}$  C, which can be converted to 78 in absolute methanol, at pH = 3, almost quantitatively.

The original p.m.r. spectrum of 78 shows that the ratio of  $\alpha$ -isomer 82 to  $\beta$ -isomer 83 is about 3 : 2. This phenomenon, in which stereochemistry unfavored  $\alpha$ -isomer 82 was predominant, can be satisfactorily explained by anomeric effect principle.

Further preparative layer chromatography of 78 upon silica gel (Solvent K) gave 82 ( $R_f = 0.6$ ), m.p. =  $75-78^{\circ}$  C and 83 ( $R_f = 0.5$ ), m.p. =  $117-120^{\circ}$  C, both as white crystals after being crystallized from ether and petroleum ether. They were unambiguously assigned to  $\alpha$  and  $\beta$  anomers respectively by analysis of their p.m.r. spectra (Figs. 14B and 15B).

Over ozonolysis of 75 produced a series of side products, which were detectable by t.l.c., and caused extreme difficulty in purifying the product. These unidentified side products probably were produced by the oxidative breakage of the benzene ring in the molecule. For this consideration, the amount of ozone was carefully

controlled in a small scale preparation and the reaction process was monitored by t.l.c.. At each interval during t.l.c., dry nitrogen was




Scheme 15 The Possible Pathways for Formation of the Fragments in the Mass Spectrum of (R,S) 2-Allyl-4-hydroxyl-N-benzyl-threo-pentanamide (77).

bubbled into the reaction solution, instead of ozone, to quench the reaction temporarily.

Ozonolysis was considered completed when the spot correspondent to the starting compound had nearly disappeared on the t.l.c. plate, (Solvent A). The plate was viewed under UV lamp. Water soluble trimethyl phosphate evolved in the reaction, were readily removed by washing the methylene solution with 20% sodium carbonate solution.

The relative stereochemistry assignment of compounds 82, 83, 84 and 85 at C<sub>5</sub>, C<sub>3</sub> and C<sub>1</sub> were achieved by the analysis of their p.m.r. spectra in Fig. 14B, 15B, 17B and 18B respectively. Each of these four isomers would be expected to adopt the two possible chair conformations, where isomers 82, 83, 84 and 85 are in their preferred conformations. The formation of intramolecular hydrogen bond facilitates the preferred conformation of 85. One proton signal, at 2.71 ppm, as a broad multiplet with  $W_H = 28$  Hz in the spectrum of 82, and one proton multiplet signal, at 2.45 ppm with  $W_H = 26$  Hz in the spectrum of 83, are assignable to the axial protons on the C<sub>3</sub> respectively. This wide spacing of the multiplet, either in the spectra of 82 or 83, clearly indicates the diaxial relationships with H<sub>2a</sub> and H<sub>4a</sub> and the axial-equatorial relations with H<sub>2e</sub> and H<sub>4e</sub>. By contrast, glycoside 84 and 85 displayed their equatorial C<sub>3</sub>-H protons at 2.72 ppm and 2.70 ppm as both a multiplet with  $W_H = 15$  Hz and  $W_H = 14$  Hz respectively. These signals contain only small vicinal couplings due to the

equatorial-equatorial relations with  $H_{2e}$  and  $H_{4e}$  and the equatorial-axial relations with  $H_{2a}$  and  $H_{4a}$ .



(85)

The i.r. and p.m.r. spectra of 82 are presented in Figs 14A and 14B.


The i.r. spectrum of 82 indicates that the NH and amino carbonyl stretching vibrations are at  $3450\text{ cm}^{-1}$  and  $1670\text{ cm}^{-1}$  respectively. The aromatic C=C absorption and the amide II band are overlapped at  $1520\text{ cm}^{-1}$  as a broad singlet.

The p.m.r. spectrum of 82 shows the three methyl protons ( $C_5\text{-CH}_3$ ) absorption at 1.19 ppm as a doublet with  $J = 6.3\text{ Hz}$  due to the coupling with the methine proton ( $C_4\text{-H}$ ). The one methine proton ( $C_1\text{-H}_e$ ), at 4.80 ppm and as a poorly resolved triplet with  $W_H = 6\text{ Hz}$ , is assignable to the equatorial proton on  $C_1$ . Its shifting to a lower field can be visualized as arising from the electronegative effect of two oxygen atoms and its equatorial orientation, (86, 87). Additionally, the small coupling indicates that the dihedral angle between  $H_e\text{-C}_1\text{-C}_2\text{-H}_aH_e$  is about  $60^\circ$  cor-

responding to the proton with equatorial orientation, (86b, 88). As expected, two diastereotopic methylene protons ( $C_2-H_aH_e$ ) are observed at 1.85 ppm as a doublet of doublets with  $J_{2a2e} = 16$  Hz as the AB pattern of an ABXY spin system, (84, 86, 89). For the two methylene protons on  $C_4$ ,  $H_{4a}$  is at 1.55 ppm, as a quartet with  $J_{4a4e} = 12$  Hz and  $H_{4e}$  appears at 1.75 ppm as a broad doublet with  $J_{4e4a} = 12$  Hz, (84, 86, 89). One methine proton signal at 2.71 ppm, with  $W_H = 28$  Hz, is assignable to the axial hydrogen on  $C_3$ . The three methoxy protons are at 3.34 ppm as a singlet. One proton multiplet, at 3.39 ppm with  $J_{5a,CH_3} = 6$  Hz is assignable to the  $C_5-H$ . Compared to 83, this signal shifts to a lower field as a consequence of the deshielding effect of the 1,3-diaxial interaction between the  $C_5-H$  and the  $C_1-OCH_3$ , (87). The two benzylic protons, appear at 4.43 ppm, as a doublet. Disappearance of the typical feature of a AB system is due to the decrease of the ratio of  $\Delta\delta/J$  which is a response to the change of steric environment in 82 compared to those in 75. The NH occurs at 5.77 ppm as a broad singlet. The five aromatic protons appear at 7.30 ppm as a multiplet.

The mass spectrum of 82, (Fig. 14C), shows the molecular ion at  $M^+/z$  263 followed by the loss of the methoxyl group giving the fragment  $M^+/z$  232. The loss of the methyl group from the molecular ion by cleavage gives the fragment  $m/z$  248. The fragment ion  $M^+/z$  106 likely attributes to the  $-NH-CH_2-Ph$  ion through the simple fission of the molecular ion. The basic benzylic fragment ion, predictably, appears at  $M^+/z$  91, (Scheme 16).

Compound 83 was assigned to  $\beta$ -anomeric glycoside. Its i.r. spectrum and p.m.r. spectra are presented in Figs. 15A and 15B.



Scheme 16 The Possible Pathways for Formation of the Fragments in the Mass Spectrum of methyl 3-(N-benzyl-carboxamido)-2,3,4,6-tetra-deoxy- $\alpha$ -DL-threo-hexopyranose (82)

The i.r. spectrum of 83 is similar to that of 82 except for the obviously difference in the finger print region. The NH stretching is present at  $3450\text{ cm}^{-1}$ . The aminocarbonyl stretching is at  $1680\text{ cm}^{-1}$ . The aromatic stretching and the amide II band are overlapped at  $1520\text{ cm}^{-1}$  as a strong singlet. The absorption corresponding to the C-O-C bending vibration are at  $1020\text{ cm}^{-1}$  and  $1080\text{ cm}^{-1}$ .

The p.m.r. spectrum of 83, Fig. 15B, shows the three methyl protons at 1.276 ppm with  $J = 6.2\text{ Hz}$  as a doublet. For two diastereotopic methylene protons ( $\text{C}_4\text{-H}_a\text{H}_e$ ), one ( $\text{H}_{4a}$ ) is at 1.45 ppm, as a quartet, and the other one ( $\text{H}_{4e}$ ), is at 1.55 ppm, as a quartet with  $J_{4e4a} = 12\text{ Hz}$ , as the AB pattern of an ABCD spin system. Their obviously different appearance with those of 82 is because of their different diastereotopic face of these two hydrogens. The  $\text{H}_{2a}$  shifts to a slight higher field, at 1.80 ppm compared to 1.84 ppm of 82 as a doublet, probably a result of the shielding effect of equatorial methoxy group on  $\text{C}_1$ , (84, 86, 89).

As expected, the signal of three methoxy protons on  $\text{C}_1$ , as a singlet at 3.50 ppm, shifts to a lower field than those of 82, (87). One methine proton ( $\text{C}_3\text{-H}_a$ ) is at 2.45 ppm as a multiplet with  $W_H = 26\text{ Hz}$ . One proton multiplet at 3.55 ppm is assignable to the  $\text{C}_5\text{-H}$ , which shifts to a higher field compared to that of 82, probably due to the absence of 1,3-diaxial interaction of the  $\text{C}_5\text{-H}$  and the  $\text{C}_1\text{-OCH}_3$ , (86, 87). Consequently assignment of the anomer for 83 is further confirmed.

As for the two methylene protons on C<sub>2</sub>, C<sub>2</sub>-H<sub>e</sub> is at 1.80 ppm as a broad doublet with J<sub>gem</sub> = 12 Hz. The C<sub>2</sub>-H<sub>a</sub> is at 1.45 ppm as a sextet with J<sub>gem</sub> = 12 Hz. One axial proton (C<sub>1</sub>-H<sub>a</sub>) appears at 4.33 ppm as a doublet of doublets with W<sub>H</sub> = 9 Hz. Predictably, this proton shifts to a higher field compared to that in 82, (87, 89). Two benzylic protons are at 4.45 ppm with J = 5.6 Hz as a doublet due to the coupling with the proton on nitrogen. The NH absorption appears at 5.70 ppm as a broad singlet. The five aromatic protons are at 7.25 ppm as a multiplet.

In the mass spectrum of 83, Fig. 15C, the molecular ion occurs at M<sup>+</sup>/z 263. The fragment ion M<sup>+</sup>/z 231 corresponds to the loss of the CH<sub>3</sub>OH from the molecular ion. The formation of fragment ion M<sup>+</sup>/z 106 (NH-CH<sub>2</sub>-Ph) is presumably produced by cleavage of the molecular ion. A tropylium fragment ion appears at M<sup>+</sup>/z 91 as a basic ion.

An analogous sequence of reactions described in the preparation of 78 was performed in the 3-epimeric isomer (77), (Scheme 7), giving a mixed acetal glycoside (80) as white amorphous crystals in 70 % yield and a small amount of 81. Compound 80 was recrystallized from ether and chloroform to give white amorphous crystals, m.p. = 57-59 ° C.

Compound 80 was subjected to column chromatography over silica (Solvent M) to afford 84, which was collected at earlier fraction, and 85 after solvent evaporation. Both 84 and 85 are white amorphous crystals, with m.p. = 57-58 ° C and m.p. = 55-56 ° C respectively after being crystallized from ethyl acetate. Compound

84 and 85 were assigned based on the analysis of their p.m.r. spectra to  $\beta$  and  $\alpha$  glycosides respectively. The infrared and p.m.r. spectra of 84 are present in Figs 17A and 17B.

The i.r. spectrum of 84, Fig. 17A, reveals the NH stretching vibration at  $3450\text{ cm}^{-1}$  and the vibration of  $-\text{CONH}-$  at  $1670\text{ cm}^{-1}$ . The bending vibration of aromatic  $\text{C}=\text{C}$  and amide II band is present at  $1520\text{ cm}^{-1}$ . The absorption of  $\text{C}-\text{O}-\text{C}$  bending vibration appears as an intense sharp signal at  $1050\text{ cm}^{-1}$ .

The p.m.r. spectrum of 84, Fig. 17B, shows the three methyl protons shifted to a higher field, as a doublet at 1.21 ppm, with  $J = 6\text{ Hz}$  compared to that of 85. The  $\text{C}_2-\text{H}_a$  is at 1.65 ppm, as a heptet with  $J_{\text{gem}} = 10\text{ Hz}$ . The  $\text{C}_2-\text{H}_e$  appears at 2.00 ppm, as a barely resolved heptet with  $J_{\text{gem}} = 12\text{ Hz}$ . The  $\text{C}_4-\text{H}_a$  appears at 1.55 ppm, as an octet with  $J_{\text{gem}} = 14\text{ Hz}$ . The  $\text{C}_4-\text{H}_e$  at 1.85 ppm,  $J_{\text{gem}} = 14\text{ Hz}$ , as a poorly resolved quintet. The  $\text{C}_3-\text{H}_e$  was observed at 2.72 ppm as a narrow multiplet with  $W_H = 15\text{ Hz}$ , which indicates its equatorial orientation. The three methoxy protons are at 3.43 ppm, as a singlet. The  $\text{C}_1-\text{H}_a$  at 4.76 ppm, with  $J_{2a, 1a} = 7.5\text{ Hz}$  and  $J_{2e, 1a} = 2.5\text{ Hz}$  ( $W_H = 12\text{ Hz}$ ), as a doublet of doublets, shifts to a lower field than that of 85 and thus is assignable to  $\beta$  anomeric orientation. The  $\text{C}_5-\text{H}$  is observed at 3.98 ppm as a doublet of quintet which predictably appears at a lower field compared to 83 and 85, (86, 87). The two benzylic protons become a doublet at 4.37 ppm with  $J = 5.7\text{ Hz}$  and the NH occurs at 6.20 ppm as a broad singlet. The five aromatic protons are at 7.30 ppm as a multiplet.

In the mass spectrum of 84, Fig. 17C, the molecular ion occurs at  $M^+/z$  263. The loss of  $\text{CH}_3\text{OH}$  from the molecular ion probably produces the fragment ion  $M^+/z$  231. A tropylium ion is at  $M^+/z$  91. The basic fragment ion  $M^+/z$  157 is presumably due to the loss of the  $\text{NH-CH}_2\text{-Ph}$  group from molecular ion by cleavage. The molecular ion  $M^+/z$  263 and fragment ion  $M^+/z$  231 are confirmed by the high resolution mass spectrum (Fig.17D).

The infrared and p.m.r. spectra of 85 are presented in Figs. 18A and 18B. In the i.r. spectrum of 85, Fig. 18A, the absorption of the NH stretching vibration shifts to a lower frequency, from  $3450\text{ cm}^{-1}$  to  $3320\text{ cm}^{-1}$ , compared to that of 84.

The p.m.r. spectrum of 85, Fig. 18B, reveals three methyl protons ( $\text{C}_5\text{-CH}_3$ ) at 1.14 ppm as a doublet with  $J = 6.2\text{ Hz}$  due to coupling with  $\text{C}_5\text{-H}_a$ . The two methylene protons ( $\text{C}_2\text{-H}_a\text{H}_e$ ) appear at 1.97 ppm as a sextet in the AB pattern of an ABCD spin system. The  $\text{C}_4\text{-H}_a$ , as an octet, is at 1.55 ppm with  $J_{\text{gem}} = 10\text{ Hz}$ , and the  $\text{C}_4\text{-H}_e$ , as a broad doublet, appears at 2.10 ppm with  $J_{\text{gem}} = 10\text{ Hz}$ . The one proton multiplet, at 2.72 ppm and with  $W_{\text{H}} = 14\text{ Hz}$ , is attributed to the  $\text{C}_3\text{-H}_e$ . Three methoxy protons appear at 3.18 ppm, as a singlet and the one methine proton on  $\text{C}_5$  ( $\text{C}_5\text{-H}_1$ ), appears at 3.80 ppm, as a doublet of sextets. The methoxy proton signal observably shifts to a higher field compared to those of 82, probably because of the shielding effect of the benzene ring and its axial orientation, (85, 86). The two benzylic protons split at 4.40 ppm, as a doublet of quartets with  $J_{\text{gem}} = 15\text{ Hz}$ , and  $J_{\text{CH}_3, \text{NH}} = 4\text{ Hz}$ , of a typical AB spin system.

The equatorial proton on C<sub>1</sub> is at 4.70 ppm, a poorly resolved triplet with  $W_H = 8.5$  Hz. The five aromatic protons appear at 7.30 ppm as a multiplet. One proton signal corresponding to the NH, which shifted to a lower field compared to 83, clearly indicates hydrogen bonding with the oxygen atom of the methoxyl group.

The mass spectrum of 85, Fig. 18C, shows the fragment ion  $M^+/z$  231 corresponding to the loss of CH<sub>3</sub>OH from the molecular ion, which is unequivocally identified by the high resolution mass spectrum, (Fig. 18D). It is not surprising that there is no signal of the molecular ion at  $M^+/z$  263. Since the formation of the hydrogen bonding between the C<sub>1</sub>-OCH<sub>3</sub> and the NH (Fig. 12C) facilitates the hydrogen rearrangement, the molecular ion is very unstable in the applied electron field and loses a methanol molecule to give fragment  $M^+/z$  231. Formation of the fragment ion  $M^+/z$  97 is presumably due to the loss of the CO-NH-CH<sub>2</sub>-Ph group from fragment  $M^+/z$  231. A tropylium ion is at  $M^+/z$  91 as a basic peak.

Treatment of 78 with lithium aluminum hydride in methylene chloride eventually gave 86 as a syrup. Further preparative layer chromatography of 86 (solvent L) afforded two anomers. The compound, with  $R_f = 0.26$ , was assigned as the  $\alpha$ -anomer (88) while the other one, with  $R_f = 0.17$ , was identified as the  $\beta$ -anomer (89).

The i. r., p.m.r. and mass spectrum of 88 are presented in Figs. 19A, 19B, 19C.

In the i. r. spectrum of 88, the C-N stretching is at 1130 cm

<sup>-1</sup> and the C-O stretching is at 1050 cm<sup>-1</sup>. The aromatic C=C absorption appears at 1600 cm<sup>-1</sup> as a weak band.

The p.m.r. spectrum of 88 shows the three methyl protons at 1.16 ppm as a doublet. The five proton signal at 1.75 ppm as a multiplet is probably attributed to the two protons on C<sub>4</sub>, the two protons on C<sub>2</sub> and the one proton on C<sub>3</sub>. The NH appears at 2.10 ppm as a broad signal. The two methylene protons adjacent to the nitrogen are present at 2.45 ppm. The three methoxy protons are at 3.34 ppm as a singlet. The two benzylic protons are at 3.76 ppm as a singlet. The proton on C<sub>5</sub> is at 3.85 ppm as a multiplet. The one equatorial proton on C<sub>1</sub> is at 4.75 ppm with  $W_H = 7.5$  Hz. The five aromatic protons are at 7.34 ppm as a multiplet. The two benzylic protons shift to a higher field and turn to be a singlet at 3.76 ppm comparing to 82.

In the mass spectrum of 88, M + 1 fragment is at M<sup>+</sup>/z 250. The loss of methyl group gave M<sup>+</sup>/z 234. The fragment M<sup>+</sup>/z 120 is presumably due to the fragment of the CH<sub>2</sub>NHCH<sub>2</sub>Ph. The tropylium ion is at M<sup>+</sup>/z 91 as a basic peak.

In the i.r. spectrum of 89, The C-O-C stretching is observed at 1080 cm<sup>-1</sup> and the C-N-C stretching appears at 1130 cm<sup>-1</sup>.

The p.m.r. spectrum of 89 shows the three methyl protons at 1.24 ppm as a doublet. The six proton signals, at 1.75 as a multiplet, are probably corresponding to the two methylene protons on C<sub>2</sub>, the two methylene protons on C<sub>4</sub>, the one methine proton on C<sub>3</sub> and the one proton on nitrogen. Predictably, the three protons on equatorial methoxyl group shift to a lower field, at 3.48 ppm, comparing to

those of 88. The two methylene protons adjacent to the nitrogen are at 2.55 ppm, which turn out to be a doublet comparing to that in 88. The axial proton on C<sub>1</sub> is present at 4.35 ppm as a doublet of doublets, with  $W_H = 14$  Hz. The two benzylic protons are at 3.80 ppm as a singlet.

In the mass spectrum of 89, the molecular ion is at  $M^+/z$  249,  $M-1$  is at  $M^+/z$  248. The loss of the methyl group is present at  $M^+/z$  234. The fragment ion  $CH_2NHCH_2Ph$  is at  $M^+/z$  120. The tropylium ion is at  $M^+/z$  91. These fragment ion are confirmed by high resolution mass spectrum, (Fig.20D). The presumed pattern of fragment ions are illustrated in Scheme 17.

The treatment of 80 with the similar reduction procedure as for 78, (Scheme 9), gave 87 in 64.7 %, as a colorless syrup. After HPLC of 87 over silica (solvent: N), two anomers, 90 ( $R_f = 0.3$ ), and 91 ( $R_f = 0.25$ ), were obtained. The compound 90 was collected at early fraction followed by 91. Compounds 90 and 91 are assigned to  $\beta$  and  $\alpha$  glycosides respectively based on the analysis of their p.m.r. spectra, Figs. 21B and 22B.

In the i.r. spectrum of 90, Fig. 21A, the strong C-O-C stretching absorption is present at  $1050\text{ cm}^{-1}$  and the C-N-C stretching appears at  $1110\text{ cm}^{-1}$ .

The p.m.r. spectrum of 90, Fig. 21B, show the three methyl protons at 1.25 ppm, as a doublet with  $J = 6$  Hz. A five proton multiplet at 1.5-1.6 ppm is assumably due to the two protons on C<sub>4</sub>, two protons on the C<sub>2</sub> and one proton on the NH. The equatorial proton on C<sub>3</sub> is at 2.15 ppm as a multiplet. A two proton signal, at

2.65 ppm as a doublet, is attributed to the two methylene protons adjacent to nitrogen. The three methoxy protons are at 3.44 ppm as a singlet. The two proton signal, at 3.81 ppm as a singlet, is due to the two benzylic protons. The one methine proton on C<sub>4</sub> is at 3.75 ppm as a multiplet and partially overlapped the benzylic protons. The one proton signal at 4.50 ppm, as a doublet and doublets, with  $W_H = 14$  Hz, corresponds to the C<sub>1</sub>-H<sub>a</sub>. The five aromatic protons are at 7.30 ppm as a multiplet.


The mass spectrum of 90, Fig. 21C, demonstrates a molecule ion at  $M^+/z$  249. The  $M^+/z$  234 and  $M^+/z$  218 correspond to the loss of the methyl group and the methoxyl group respectively. The  $M^+/z$  120 is due to the fragment CH<sub>2</sub>NHCH<sub>2</sub>Ph. The tropylium ion is at  $M^+/z$  91. These fragments are all proved by high resolution mass spectrum (Fig. 21D) and the presumed fussion pattern is elucidated in Scheme 17.

The i. r. spectrum of 91 is similar to that of 90. The strong C-N-C stretching vibration is at 1120 cm<sup>-1</sup> and the C-O-C appears at 1050 cm<sup>-1</sup>.

The p. m. r. spectrum of 91 shows the three methyl protons at 1.15 ppm as a doublet with  $J = 6$  Hz. The two methylene protons on C<sub>4</sub> overlap the two methylene protons on C<sub>2</sub> and the proton on the nitrogen at 1.45-1.85 ppm. The two methylene protons adjacent to nitrogen, are evident at 2.80 ppm as a triplet which shift to a higher field comparing to that in 78. The axial methoxy group, as expected, shifts to a higher field compared to its equatorial anomer (90), at 3.31 ppm, as a singlet. One proton singlet at 3.95 ppm is

due to the C<sub>5</sub>-H<sub>a</sub>. The equatorial proton on C<sub>1</sub> is present at 4.65 ppm as a broad singlet, with W<sub>H</sub> = 7 Hz. The two benzylic protons are at 3.80 ppm as a singlet. A five proton multiplet signal, at 7.30 ppm, attributes to the aromatic protons.

The mass spectrum of 91 shows a similar fragment pattern to that of 90. The molecular ion is at M<sup>+</sup>/z 249. The M<sup>+</sup>/z 234 and M<sup>+</sup>/z 218 are visualized by arising as a consequence of losing the methyl and methoxyl group respectively. The M<sup>+</sup>/z 120 corresponds to the fragment CH<sub>2</sub>NHCH<sub>2</sub>Ph. The M<sup>+</sup>/z 91 is due to the tropylium ion.



Scheme 17 The Possible Pathways for Formation of the Fragments in the Mass Spectrum of Methyl-3-N-(benzylamino-methyl)-2,3,4,6-tetra-deoxy- $\beta$ -DL-erythro-hexopyranose (90)

## EXPERIMENT

All melting points were recorded on a Fischer-Johns melting point apparatus and were uncorrected. Infrared spectra were taken on a Perkin Elmer Infracord 710 spectrometer, using sodium chloride cell with methylene chloride as a solvent. Mass spectra were recorded on a V.G. 7070EHF mass spectrometer with a 70 FAB system. A Bruker AM-300 spectrometer was used to make all p.m.r. spectra and  $^{13}\text{C}$  n.m.r. spectrum with  $\text{CDCl}_3$  as a solvent and tetramethylsilane (TMS) as an internal reference except those presented in figs. 8A, 10B, 11B, which were made on a Varian EM-360 spectrometer. The anomers (90) and (91) were isolated on a HPLC instrument, Spectra-Physics 3000B, with a Modle 230 UV detector and silica column.

Preparative layer chromatograms were obtained on 20 X 20 cm (plate thickness: 0.2 cm) silica gel plates (E. Merck), which were activated at  $120^\circ\text{C}$ . UV light and iodine were used for visualization. Thin layer chromatograms were obtained on 0.2 mm silica gel 60 F<sub>254</sub> plates. (E. Merck, Darmstadt, Germany). Column chromatography was performed with silica gel 60 (E. Merck Darmstadt, Germany). Absolute methanol was distilled from magnesium metal immediately prior to use. Tetrahydrofuran (THF) was freshly distilled from sodium metal. Solutions were concentrated under reduced pressure using a rotary evaporator.

The 0.5 M potassium phosphate buffer solution (pH = 7) was used to prepare buffered plates for preparative layer chromatography.

The solvent systems used for the experiments are listed as follows:

Solvent A: chloroform-acetone, 9:1, v/v.

Solvent B: chloroform:acetone, 90:5, v/v.

Solvent C: methylene chloride:acetone, 10:0.3, v/v.

Solvent D: benzene:acetone:t-butanol, 10:0.5:0.5, v/v.

solvent E: benzene:ethylacetate, 2:1, v/v.

Solvent G: petroleum ether:acetone, 3:1, v/v.

Solvent H: chloroform:acetone 10:1, v/v.

Solvent I: chloroform.

Solvent J: benzene:acetone, 10:2, v/v.

Solvent K: methylene chloride.

Solvent L: ethyl acetate.

Solvent M: cyclohexane:acetone, 2.5:1, v/v.

## EXPERIMENT

### PART A: SYNTHESIS OF 1-DEOXY-N,N-BIS-DEMETHYL-PYRROMYCIN (58)

#### ISOLATION OF AKLAVINONE (55)

A pigmented compound was obtained from the ethyl acetate extracts of cultured and mycelial cakes of *Streptomyces Galilaeus* var. *Siwenensis*, (68). Further purification of this compound by preparative layer chromatography (solvent A) gave orange amorphous solids of which physical and spectroscopic properties were similar to aclacinomycin A reported by H. Umezawa et al., (76).

By acid hydrolysis of this amorphous solids (800 mg) in sulfuric acid (0.3 N, 50ml) at 85°C for 3 hr, a yellow precipitate was collected by filtration. This yellow precipitate was washed with water (20 ml, three times), and then collected by filtration. The yellow compound was recrystallized from acetone-ether, yielding 330 mg of aklavinone (55), as orange crystalline needles.

The physical and spectroscopic data of 55 is identical to the literature, (77-79).

m.p. = 169-173°C, Lit. m.p. = 171°C.

i.r. (cm<sup>-1</sup>), Fig. 1A:

3550 (OH), 3475 (chelated phenolic OH), 1730 (-COOCH<sub>3</sub>), 1675 (C=O), 1620 (chelated C=O).

p.m.r. (ppm), (CDCl<sub>3</sub>), Fig. 1B-1:

1.10 (t, 3H, OCH<sub>3</sub>), 1.50-1.70 (m, 2H, C<sub>13</sub>-2H), 2.25 (broad d, 1H, H<sub>8a</sub>), 2.60 (dd, 1H, H<sub>8e</sub>), 3.50 (s, 1H, C<sub>9</sub>-OH), 3.70 (s, 3H, OCH<sub>3</sub>), 3.92 (s, 1H, C<sub>7</sub>-OH), 4.13 (s, 1H, C<sub>10</sub>-H), 5.35 (s, broad, 1H, H<sub>7e</sub>), 7.30 (d, 1H, H<sub>11</sub>), 7.70 (m, 3H, aromatic protons), 11.90 (s, 1H, 3-OH), 12.70 (s, 1H, 6-OH).

Double Irradiation p.m.r. Spectrum (ppm), (CDCl<sub>3</sub>), Fig. 1B-2.

#### PREPARATION OF 1-CHLORO-4-O-(P-NITRO-BENZOYL)-3-N-TRIFLUOROACETYL DAUNOSAMINE (50)

A) To a solution of 3-N-trifluoroacetyl daunosamine (53) (530 mg) in methylene chloride (70 ml), was added p-nitrobenzyl chloride (1.35 g) and pyridine (1.5 ml) at room temperature. The solution was stirred magnetically at 40°C in an oil bath under anhydrous condition for a period of 15 hr.

The solution was concentrated under the reduced pressure and extracted with anhydrous ether (100 ml). After filtration of the solution, a white solid residue was collected and washed with anhydrous ether (100 ml). The combined ether solution was evaporated to dryness under reduced pressure. The residue was purified by flash column chromatography over silica (Solvent L) to give in order of elution, p-Nitrobenzoic anhydride and the protected sugar 54 (1.1 g) (1,4-di-O-(p-nitrobenzoyl)-3-N-trifluoroacetyl-daunosamine). The yield was 80%. The product 54 was further recrystallized from chloroform as white crystals.

The melting point and spectroscopic data for 54:

m.p. = 195-197°C, Lit. 197.0-198.5°C, (53).

i.r. (cm<sup>-1</sup>), Fig. 2A:

3450 (NH), 1750 (C=O), 1610 (aryl), 1540 (NO<sub>2</sub>).

p.m.r. (ppm), (CDCl<sub>3</sub>), Fig. 2B:

1.20 (d, 3H, CH<sub>3</sub>), 2.20 (q, 1H, C<sub>2</sub>-H<sub>a</sub>), 2.35 (d, 1H, C<sub>2</sub>-H<sub>e</sub>), 4.10 (m, 1H, C<sub>5</sub>-H<sub>a</sub>), 4.55 (m, 1H, C<sub>3</sub>-H<sub>a</sub>), 5.45 (s, 1H, C<sub>4</sub>-H<sub>e</sub>), 6.15 (d, 1H, C<sub>1</sub>-H<sub>a</sub>), 6.65 (s, 1H, NH), 8.30 (m, 8H, aromatic protons)

B) To the stirred solution of 54 (210 mg) in methylene chloride (20 ml) in a flask in an ice bath, was passed anhydrous hydrogen chloride through a gas dispersion tube for 10 minutes. After being stirred for an additional 20 min, while the temperature remained unchange (0°C), the solution was filtered. The filtrate was evaporated to dryness under the reduced pressure to give a white foamy residue 50. This unstable foamy residue 50 was dissolved in methylene chloride (10 ml) and evaporated to dryness. This operation was repeated once more until the residue is free of hydrogen chloride. Compound 50, without further purification, was allowed to condense with aklavinone (55).

PREPARATION OF METHYL 4-O-(P-NITRO-BENZOYL)-3-N-TRIFLUORO-ACETYL-DAUNOSAMINE (46) AND THE TWO ANOMERS, 47 AND 48

To the stirred solution of methyl 3-N-trifluoroacetyl-daunosamine (45) (1.056 g) in methylene chloride (10ml) and pyridine (10ml) was added p-nitrobenzoyl chloride (966 ml) at 0°C. After being stirred at

0 °C for one hr, the solution was allowed to warm to 25 °C and stirred for additional 14 hr. Then the solution was evaporated under reduced pressure to give a syrupy residue.

The residue was dissolved in chloroform (30 ml) and the solution was washed by a dilute sulfuric acid solution (3N, 10 ml, three times), and then a ice cold saturated sodium carbonate solution (10 ml, three times) and water (10 ml, three times). The organic layer was separated out, dried over magnesium sulfate (MgSO<sub>4</sub>) and then filtered. The filtrate was evaporated to dryness to afford 46 as a white amorphous solid (1.102 g), as a mixture of two anomeric isomers from ether. The yield was 96.4 %. m.p. = 70-74 C. Preparative layer chromatography of 46 over silica gel (Solvent B) gave the two anomers, e.g.  $\alpha$ -anomer 47 (Rf = 0.5) and  $\beta$ -glycoside 48 (Rf = 0.45), both as white amorphous solids from ether.

The spectroscopic data for 46:

i. r. (cm<sup>-1</sup>), Fig. 3A:

3420 (NH), 1730 (CONHCF<sub>3</sub>), 1720 (C=O), 1530, 1360 (NO<sub>2</sub>), 1620 (phenyl nucleus), 1190 (C-O-C), 2850 (OCH<sub>3</sub>).

The spectroscopic data for glycoside 47:

p.m.r. (ppm), (CDCl<sub>3</sub>), Fig. 3B:

1.20 (d, 3H, C<sub>5</sub>-CH<sub>3</sub>), 1.98-2.05 (m, 2H, C<sub>2</sub>-H<sub>2</sub>), 3.41 (s, 3H, C<sub>5</sub>-OCH<sub>3</sub>), 4.20 (dd, 1H, C<sub>5</sub>-H), 4.68 (m, 1H, C<sub>3</sub>-H), 4.93 (s, broad, 1H, Wh = 6 Hz C<sub>1</sub>-H), 5.42 (s, broad, 1H, C<sub>4</sub>-H), 6.46 (d, broad, 1H, NH), 8.28 (m, 4H, aromatic hydrogens).

Mass spectrum (M<sup>+</sup>/z), Fig. 3C:

375 (M-OCH<sub>3</sub>), 304, 195, 150 (O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CO, 100%), 58.

The spectroscopic data for the glycoside 48:

p.m.r. (ppm), Fig. 4B:

1.28 (d, 3H, CH<sub>3</sub>), 1.85 and 2.15 (two sets of doublet, 2H, CH<sub>2</sub>), 3.58 (s, 3H, OCH<sub>3</sub>), 3.87 (q, 1H, C<sub>5</sub>-H), 4.70 (m, 1H, C<sub>3</sub>H), 4.95 (s, 1H, C<sub>4</sub>H), 5.45 (s, 1H, C<sub>1</sub>H), 6.20 (d, 1H, NH), 8.30 (q, 4H, aromatic protons).

Mass spectrum (M<sup>+</sup>/z), Fig. 4C:

375 (M-OCH<sub>3</sub>), 304, 195, 150 (O<sub>2</sub>NC<sub>6</sub>H<sub>4</sub>CO, 100%), 58.

**PREPARATION OF 1-BROMO-4-O-(P-NITRO-BENZOYL)-3-N-TRIFLUOROACETYL-DAUNOSAMINE (49)**

To the stirred solution of 46 (300 mg) in methylene chloride (30 ml) in a flask was bubbled anhydrous hydrogen bromide through a gas dispersion tube for 30 min, at 0°C. After that, the reaction solution was evaporated under reduced pressure to remove methylene chloride, HBr and methanol evolved in reaction to dryness. The residue was dissolved in methylene chloride (30 ml), and the solution was evaporated to dryness. This operation was repeated once more until the residue 49 was free of hydrogen bromide. This compound, without further purification, was permitted directly to undergo glycosidation with aklavinone (55).

**PREPARATION OF 7-O-4'-O-(P-NITRO-BENZOYL)-3'-N-(TRIFLUOROACETYL)- $\alpha$ -DAUNOSAMINYL-AKLAVINONE (56) AND THE GLYCOSID 57**

Method A:

To the flask, containing crystalline aklavinone (55) (120 mg), the 1-chlorosugar 50 (100 mg) and freshly ground molecular sieve 3A (300 mg), was injected anhydrous methylene chloride (35 ml) through a rubber stopper followed by silver trifluoromethane sulfonate (80 mg) addition in anhydrous ether (10 ml) in the same manner. The solution was stirred at room temperature in darkness for 4 hr and then filtered. The filtrate was washed with 5 % NaCl solution (10 ml, two times). The organic layer was dried ( $\text{NaSO}_4$ ) and filtered through a Butch funnel. The filtrate was evaporated to dryness under reduced pressure to give a orange foamy residue. The residue was separated by a column chromatography over silica (Solvent C) to give 56 as a major product and a small amount of 57. Compound 56 was slowly crystallised from methylene chloride and ether, yielding 90 mg of orange crystalline needles. m.p. = 174 - 177°C. The yield was 40 % after crystallization.

The spectroscopic data for 56:

i.r. ( $\text{cm}^{-1}$ ), Fig. 5A:

3540 (OH), 3420 (NH), 1735 (broad and intense,  $-\text{COOCH}_3$ ,  $-\text{C}_6\text{H}_4-\text{COO}-$ ,  $\text{NHCOCF}_3$ ), 1680 (C=O), 1630 (chelated C=O), 1620 (aromatic), 1535 ( $\text{NO}_2$ ).

p.m.r. (ppm), Fig. 5B-1:

1.11 (t, 3H,  $J = 6.2$  Hz,  $\text{C}_{13}-\text{CH}_3$ ), 1.26 (d, 3H,  $J = 7.0$  Hz,  $\text{C}_5'-\text{CH}_3$ ), 1.54 and 1.79 (two sets of m, 2H,  $\text{C}_{13}-\text{H}_2$ ), 2.10 (m, 2H,  $\text{C}_2'-\text{HaHe}$ ), 2.34 (broad d, 1H,  $J_{8a8e} = 15$  Hz,  $J_{8a7e} = 1$  Hz,  $\text{C}_8-\text{H}_a$ ), 2.62 (dd, 1H,  $J_{8a8e} = 15$  Hz,  $J_{7e8e} = 5$  Hz,  $\text{C}_8-\text{H}_e$ ) 3.70 (s, 3H,  $\text{C}_{10}-\text{COOCH}_3$ ), 4.20 (s, 1H,  $\text{C}_9-\text{OH}$ ), 4.05 (s, 1H,  $\text{C}_{10}-\text{H}_e$ ), 4.47

(m, 2H, C<sub>3</sub>'-H<sub>a</sub> and C<sub>5</sub>'-H<sub>a</sub>, J<sub>C5'-H,CH3</sub> = 7 Hz), 5.47 (broad s, 1H, C<sub>4</sub>'-H<sub>e</sub>), 5.64 (broad s, 1H, C<sub>1</sub>'-H<sub>e</sub>), 5.38 (broad d, 1H, C<sub>7</sub>-H<sub>e</sub>), 6.20 (broad doublet, 1H, NH), 7.73 (s, 1H, C<sub>11</sub>-H), 7.33 (d, 1H, J<sub>2,3</sub> = 8 Hz, C<sub>3</sub>-H), 7.85 (d, 1H, J<sub>1,3</sub> = 1 Hz, C<sub>1</sub>-H), 7.72 (t, 1H, C<sub>2</sub>-H), 8.33 (m, 4H, four aromatic protons), 12.00 (s, 1H, C<sub>4</sub>-OH), 12.78 (s, 1H, C<sub>6</sub>-OH).

<sup>13</sup>C n.m.r. spectrum (ppm), Fig. 5B-2:

125 (s, C<sub>1</sub>), 126 (s, C<sub>2</sub>), 121 (s, C<sub>3</sub>), 157.5 (s, C<sub>4</sub>), 192 (s, C<sub>5</sub>), 157 (s, C<sub>6</sub>), 67 (s, C<sub>7</sub>), 32 (s, C<sub>8</sub>), 73 (s, C<sub>9</sub>), 47 (s, C<sub>10</sub>), 122 (s, C<sub>11</sub>), 181 (s, C<sub>12</sub>), 35 (s, C<sub>13</sub>), 14 (s, C<sub>14</sub>), 165 (s, C<sub>15</sub>), 53 (s, C<sub>16</sub>), 134 (s, C<sub>17</sub>), 131.5 (s, C<sub>18</sub>), 133.5 (s, C<sub>19</sub>), 131 (s, C<sub>20</sub>), 143 (s, C<sub>21</sub>), 135 (s, C<sub>22</sub>), 101 (s, C'<sub>1</sub>), 30 (s, C'<sub>2</sub>), 58 (s, C'<sub>3</sub>), 72.5 (s, C'<sub>4</sub>), 72 (s, C'<sub>5</sub>), 17 (s, C'<sub>6</sub>), 171 (s, C'<sub>7</sub>), 115, 116, 117 and 118 (quartet, C'<sub>8</sub>), 161.5 (s, C'<sub>9</sub>), 161 (s, C''<sub>1</sub>), 138 (s, C''<sub>2</sub>), 132 (s, C''<sub>3</sub>) and 152 (s, C''<sub>4</sub>).

Mass spectrum (M<sup>+</sup>/z), (1):

M<sup>+</sup> = 786 (FAB mass-spectrum)

The spectroscopic data for 57:

i.r. (cm<sup>-1</sup>), (1):

3600, 3520 (OH), 3470, 3430 (NH<sub>2</sub>), 3500 to 3100 (chelated OH), 1735 (COOCH<sub>3</sub>), 1680 (C=O), 1635 (chelated C=O), 1610, 1580 (aromatic).

p.m.r. (ppm), Fig. 6B:

1.10 (t, 3H, C<sub>13</sub>-CH<sub>3</sub>), 1.51 (d, 3H, C<sub>5</sub>'-CH<sub>3</sub>), 1.52 and 1.55 (two sets of multiplet, 2H, C<sub>13</sub>-H<sub>2</sub>), 2.3 and 2.0 (two sets of multiplet, C'<sub>2</sub>-H<sub>2</sub>), 2.30 and 2.60 (two sets of multiplet, 2H, C<sub>8</sub>-H<sub>2</sub>), 3.70

(s, 3H, OCH<sub>3</sub>), 3.9 (s, 1H, C<sub>10</sub>-H), 4.2 (s, 1H, C<sub>9</sub>-H), 4.5 (d, 1H, C'<sub>5</sub>-H), 4.7 (m, 1H, C'<sub>3</sub>-H), 5.4 (dd, 1H, C'<sub>1</sub>), 5.65 (d, 1H, C'<sub>4</sub>-H), 5.75 (s, 1H, C<sub>7</sub>), 7.35 (d, 1H, C<sub>3</sub>-H), 7.6 (d, 1H, C<sub>2</sub>-H), 7.75 (s, H, C<sub>11</sub>-H), 7.9 (d, 1H, C<sup>1</sup>-H), 8.5 (q, 4H, benzene protons), 11.86 (s, 1H, C<sub>4</sub>-OH), 13.12 (s, 1H, C<sub>6</sub>-OH).

Method B:

Aklavinone (50) (200 mg), silver trifluoromethane sulfonate (380 mg) and finely powdered molecular sieve 3A (5 g) was placed in stirred anhydrous methylene chloride (100 ml). The solution was magnetically stirred at 40 - 45°C for 20 hr in darkness. Three one equivalent portions of freshly prepared 1-bromosugar 49 were added at 0, 5 and 10 hr interval and the additional silver trifluoromethane sulfonate (100 mg) was added at 10 hr interval. The reaction completed as judged by t.l.c. (Solvent D).

After being cooled to 0°C, the solution was filtered and the solid residue was washed with methylene chloride (15ml, 2 times). The filtrate and washing were combined, and evaporated to dryness to give a orange residue. Then the residue was dissolved in CHCl<sub>3</sub> (30 ml) followed by washing with 20 % KI solution (15 ml, two times) and water (10ml, two times). The organic layer was separated, dried over anhydrous sodium sulfate and filtered. The filtrate was evaporate under reduced pressure to dryness to give a orange residue. The preparative layer chromatography of the residue upon buffered silica gel (solvent E) afforded 56 as a major compound. Compound 56 was recrystallized from methylene chloride and ether, yielding 95 mg of

yellow crystalline needles. The yield was 26.9 % after recrystallization.

#### PREPARATION OF 1-DEOXY-N,N-BIS-DEMETHYL-PYRROMYCIN (10)

To a stirred solution of methanol (8 ml), saturated potassium carbonate solution (3 ml) and water (3 ml) was added 56 (90 mg) in tetrahydrofuran (8 ml). The mixture was stirred at room temperature for 15 hr and then cooled in an ice bath. The solution was adjusted to pH = 9 by dilute hydrochloric acid (0.5 %), and then exhaustively extracted by chloroform (30 ml, three times). The combined extract was dried over anhydrous magnesium sulfate and filtered. After the filtrate being evaporated to dryness, a dark orange residue was obtained. The residue was subjected to preparative layer chromatography upon silica gel to give 1-deoxy-N,N-demethyl-pyrromycin (10) (25 mg) in 37.9% yield, as an amorphous solid after being crystallised from methylene chloride and ether.

The physical and spectroscopic data for 10:

m. p = 132-143 C (decomposed).

i.r. ( $\text{cm}^{-1}$ ), (Fig. 6A), (1):

3600, 3520 (OH), 3470, 3430 ( $\text{NH}_2$ ), 3500-3100 (chelated OH), 1735 ( $\text{COOCH}_3$ ), 1680 (C=O), 1635 (chelated C=O), 1610, 1586 (aryl).

## EXPERIMENT

### PART B: PREPARATION OF METHYL 3-N-(BENZYL-CARBOX-AMIDO)-2,3,4,6-TETRADEOXY-DL-THREO-HEXOPYRANOSE (78) AND ITS 3-EPIMER (80)

#### PREPARATION OF 2,2-DIALLY-DIETHYLMALONATE (64)

To a stirred solution of acetone (6 litre), diethylmalonate (63) (607 ml, 4 moles) and powdered potassium carbonate (2800 g, 20 moles) was added allyl bromide (1384 ml, 16 moles) in one portion at room temperature. Then the reaction solution was heated to reflux with vigorously stirring over a period of 4 days.

During the reaction, a rubber balloon was made on the top of condenser and mercury seal was required so that a little pressure was created inside of the flask to enhance the reaction rate. After 4 days, the reaction was completed as judged by t.l.c., (Solvent G).

After being cooled to 0°C, the reaction solution was filtered to remove the potassium carbonate residue. The cake of potassium carbonate was washed with acetone (400 ml, three times). The filtrate and washing were combined and then evaporated to remove acetone to give a slight yellow liquid. After distillation of the liquid under reduced pressure at 87-89°C/1.5 mm, a colorless liquid 64 (912 g) was obtained in 95% yield.

The spectruscopic data for 64:

i. r. (cm<sup>-1</sup>) Fig. 8A:

1720 (intense singlet, COOEt), 1640 (weak, C=C), 1200 (broad singlet, C-O-C).

p.m.r. (ppm), Fig. 8B:

1.32 (t, 6H, two CH<sub>3</sub>), 2.55 (d, 4H, four allylic protons), 4.17 (q, 4H, two CH<sub>2</sub>), 4.86-5.80 (m, 6H, six olefinic protons).

#### PREPARATION OF 2,2-DIALLYL-MALONIC ACID (65)

2,2-diallyl-malonate (4 mol, 960 g) (64) was added to the stirred solution of methanol (2.4 L), water (4.3 L) and potassium hydroxide (16 mol, 896 g). The solution was heated to reflux with stirring for 15 hr. After being cooled to room temperature, the solution was carefully neutralized and adjusted to pH 2-3 by adding dropwise cooled concentrated HCl with efficient stirring at about 0 °C. Then the solution was extracted completely with methylene chloride (500 ml, three times). The extracts were combined and dried over anhydrous magnesium sulfate followed by filtration. The filtrate was evaporated under reduced pressure to dryness to give 65 (669 g), in 91 % yield, as white crystals after being recrystallized from chloroform.

The spectroscopic data for 65:

m.p. = 126-128 °C

i.r. (cm<sup>-1</sup>), Fig. 9A:

3550 (OH monomers), 3300-3000 (OH dimers), 1760 (C=O monomers), 1710 (C=O dimers), 1650 (C=C weak).

p.m.r. (ppm), Fig. 9B:

2.70 (d, 4H, four allylic protons), 5.16 (poorly resolved sextet, 2H, two  $H_{\text{trans}}$ ), 5.20 (poorly resolved doublet, 2H, two  $H_{\text{cis}}$ ), 5.70 (m, 2H, two  $H_{\text{gem}}$ ).

Mass spectra ( $M^+/z$ ), Fig. 9C:

185 ( $M+1$ ), 166 ( $M-H_2O$ ), 125 [ $M-(H_2O)-(CH_2=CHCH_2)$ ], 79 [ $M+1-(H_2O)-(CO_2)-(CO)$ ].

#### PREPARATION OF 2-ALLYL-4-PENTENOIC ACID (66)

2,2-diallylmalonic acid (65) (2 mol, 280g) was placed into a solution of acetic acid (1.5 L), water (600 ml) and DMF (1.1 L). The mixture was stirred under reflux for 25 hr. The reaction process was monitored by t.l.c. (Solvent H). Then the reaction solution was exhaustively extracted with chloroform (400 ml, three times). The extracts were combined and evaporated under reduced pressure to give a liquid. The liquid was distilled at 98-100°C/2.5 mm to give 66 (266 g) as a colourless liquid. The yield was 95 %.

The spectroscopic data for 66:

i.r. ( $\text{cm}^{-1}$ ), Fig. 10A:

3500 (OH monomers), 3300-3000 (OH dimmers), 1742 (C=O monomers), 1702 (C=O dimmers), 1650 (mediate, C=C).

p.m.r. (ppm), Fig. 10B:

2.37 (broad d, 4H, four allylic protons), 4.96 (broad s, 2H, two  $H_{\text{cis}}$ ), 5.20 (poorly resolved broad doublet, 2H, two olefinic  $H_{\text{trans}}$ ), 5.83 (m, 2H, two olefinic  $H_{\text{gem}}$ ), 11.5 (s, 1H, one carboxylic proton).

Mass spectrum ( $M^+/e$ ), Fig. 10C:

$M^+/z$  140 (molecular ion), 95 (M-COOH, 14%), 99 [M-(CH<sub>2</sub>-CH=CH<sub>2</sub>)], 44 (18 %), 43 (100 %).

PREPARATION OF (R,S) 2-ALLYL-4-METHYL- $\gamma$ -BUTYROLACTONE  
(67)

2-Allyl-4-pentenoic acid (66) (16 g) was added in one portion to a stirred solution of hexane (900 ml), p-toluenesulfonic acid monohydrate (16 g) and water (10 ml) in a 3 litre round-bottomed flask fixed with a 50 ml Black-stock water trap and a condenser.

The reaction solution was heated to reflux with stirring for 2 days. The reaction process was monitored by t.l.c., which revealed formation of compound 67, ( $R_f = 0.65$ ), and high boiling point by-products, ( $R_f = 0.7$ ), (Solvent N). After cooling to room temperature, the solution was transferred to a separatory funnel. The organic hexane layer was separated from a small amount of solvated brown p-toluenesulfonic acid which could be used for recycle. The hexane solution was evaporated under reduced pressure to reduce the total volume of the solution to about 200 ml.

The remained solution was washed with an ice cold solution of sodium bicarbonate (50%, w/v), (30 ml, two times), and then ice cold water (30 ml, two times). The organic layer was separated from the aqueous solution, dried over anhydrous magnesium sulfate (MgSO<sub>4</sub>) and filtered. The filtrate was evaporated to dryness to give a pale brown liquid. The distillation of the liquid under reduced pressure (87-90°C/2.6 mm) gave the colorless viscous liquid 67 (9 g) in 56.3% yield.

The spectroscopic data for 67:

i.r. ( $\text{cm}^{-1}$ ), Fig. 11A:

1762 (very intense, COO- stretching), 1640 (mediate shoulder, C=C), 1180 (intense, CO-O-C bending).

p.m.r. (ppm), Fig. 11B:

1.38 (d, 3H,  $\text{C}_4\text{-CH}_3$ ), 2.00-3.00 (m, 5H,  $\text{C}_3\text{-CH}_2$ ,  $\text{C}_2\text{-H}$  and the two allylic protons), 4.50 (sxtet, 1H,  $\text{C}_4\text{-H}$ ), 5.00 (s, broad, 1H,  $\text{H}_{\text{cis}}$ ), 5.20 (broad doublet, 1H,  $\text{H}_{\text{trans}}$ ), 5.50-6.00 (m, 1H, the olefinic  $\text{H}_{\text{gem}}$ ).

Mass spectrum ( $\text{M}^+/\text{e}$ ), Fig. 11C:

140 (molecular ion), 141 ( $\text{M}+1$ ), 125 ( $\text{M}-\text{CH}_3$ ), 96 ( $\text{M}-\text{CO}_2$ ).

High resolution mass spectrum ( $\text{M}^+/\text{z}$ ), Fig. 11D:

$\text{C}_8\text{H}_{12}\text{O}_2$ : calculated 140.0837324, observed: 140.084244.

**PREPARATION OF (R,S) 2-ALLYL-N-BENZYL-4-HYDROXY-ERYTHRO-PENTAN-AMIDE (75) AND (R,S) THREO DIASTEREOMER 77**

Sodium hydride (9.6 g, 0.4 mol), which was washed with petroleum ether, was immediately placed into the stirred solution of absolute tetrahydrofuran (THF), (1.8 L), and benzylamine (37.4 g, 0.35 mol) at room temperature. After being stirred at room temperature for one hr, the solution was heated to reflux and stirred for additional 2 hr. During the reaction, nitrogen balloon was made at top of condenser to avoid any possibility of the oxidation of benzylamine by air.

To this solution, 2-allyl-4-hydroxy- $\gamma$ -butyrolactone (67) (42 g, 0.30 mol) in 500 ml of tetrahydrofuran (THF) was added dropwise, over a period of one hr, with stirring under reflux. The additional

15 hrs. was permitted to complete the reaction. The reaction process was monitored by t.l.c. (Solvent A).

After being cooled to 0°C, hydrochloric acid (10 N) was added dropwise with efficient stirring to neutralize the solution to pH 7-6. The solution was evaporated under reduced pressure to remove THF solvent. To the remained solution, 100 ml of methylene chloride was added. The solution was washed with ice cold saturated sodium chloride solution (20 ml, two times). Then the organic layer was separated, dried over anhydrous sodium sulfate and filtered. The filtrate was evaporated under reduced pressure to dryness to give a pale brown syrup (45 g), which was subjected to column chromatography over silica, (Solvent I). Compound 75 was first eluted out and was a pale yellow syrup (15 g) after solvent evaporation. Compound 77 was collected at a latter fraction, after solvent evaporation and recrystallized from a solution of ether and chloroform (10:1 v/v), yielding 18 g of white crystals, m.p. = 69-70°C. The total yield of 75 and 77 was 44.5 % after column chromatography.

The spectroscopic data for 75:

i. r. (cm<sup>-1</sup>) Fig. 12A

3580 (monomer OH stretching), 3430 (dimmer OH and NH stretching), 3320 (polymer OH and NH stretching), 1670 (CONH, broad), 1620 (C=C, weak shoulder), 1520 (broad, aromatic C=C and the amide II band).

p.m.r. (ppm), Fig. 12B:

1.19 (d, 3H, -CH<sub>3</sub>, J=6.2 Hz), 1.57 and 1.80 (two sets of a double of triplets, 2H, two allylic protons), 1.97 (d, 1H, OH, J=4.5 Hz),

2.20 (m, 1H, methine proton to carbonyl group, C<sub>2</sub>-H), 2.45 (m, 2H, two methylene protons on C<sub>3</sub>), 3.85 (m, 1H, C<sub>4</sub>-H), 4.45 (dq, 2H, two benzylic protons, J<sub>gem</sub> = 15 Hz, J<sub>CH<sub>2</sub>,NH</sub> = 6 Hz), 5.10 (s, broad, 1H, one olefinic H<sub>trans</sub>), 5.03 (d, broad, 1H, one olefinic H<sub>cis</sub>), 5.75 (m, 1H, one olefinic H<sub>gem</sub>), 6.00 (s, broad, 1H, NH), 7.73 (m, 5H, five aromatic protons).

Mass spectra (M/e), Fig. 12C:

247 (molecular ion), 229 (M-H<sub>2</sub>O), 202 [M-(CH<sub>3</sub>CH<sub>2</sub>OH)], 189 (M-58, 30%), 149, 106 (NHCH<sub>2</sub>Ph, 48%), 91 (CH<sub>2</sub>-Ph, 100%).

The spectroscopic data for 77:

i.r. (cm<sup>-1</sup>), Fig. 13A:

3580 (OH stretching, free H bonding), 3430 (dimmer OH and monomer NH stretching), 3320 (OH and NH stretching, intermolecular H bonding), 1670 (CONH, broad, intense), 1640 (shoulder, mediate, C=C stretching overlaps with CONH absorption), 1520 (aromatic C=C and amide II band).

p.m.r. (ppm), Fig. 13B:

1.19 (d, 3H, CH<sub>3</sub>, J = 6.2 Hz), 1.60 and 1.85 (pentet and double of triplets, 2H, two allylic protons), 2.25 (m, 1H, one methine proton adjacent to carbonyl group, C<sub>2</sub>-H), 2.35 (m, 2H, two methylene protons on C<sub>3</sub>), 2.08 (s, broad, 1H, OH), 3.85 (m, 1H, C<sub>4</sub>-H), 4.45 (dq, 2H, two benzylic protons), 5.03 (d, broad, 1H, one H<sub>cis</sub>), 5.10 (s, broad, 1H, one H<sub>trans</sub>), 5.75 (m, 1H, one H<sub>gem</sub>), 6.00 (s, broad, 1H, NH), 7.73 (m, 5H, five aromatic protons).

Mass spectrum (M<sup>+</sup>/e) Fig. 13C:

247 ( $M^+$  molecular ion), 229 ( $M - H_2O$ ), 202 ( $M - CH_3CHOH$ ), 189 ( $M - CH_3COH=CH_2$ ), 106 ( $NH-CH_2-Ph$  50%), 91 ( $CH_2-Ph$ , 100%).

PREPARATION OF METHYL 3-N-(BENZYLAMINO-CARBONYL)-  
2,3,4,6-TETRADEOXY-DL-THREO-HEXOPYRANOSE (78) AND  
ANOMERS 82 AND 83

To the solution of (R,S) 2-allyl-N-benzyl-4-hydroxy-erythro-pentanamide (75) (1.5 g) in absolute methanol (150 ml) was bubbled dry ozone ( $O_3$ ), through a gas dispersion tube, with a stirring at -20 to -25 C. The reaction time was permitted to be 17 minutes as judged by t.l.c.. During the interval of t.l.c., dry nitrogen gas was passed into the reaction solution instead of ozone ( $O_3$ ) to stop the reaction temporarily. Then 3 ml of freshly distilled trimethyl phosphite [ $P(OCH_3)_3$ ] was added into the solution. Then the solution was heated to reflux with a stirring for 16 hr. After cooling to room temperature, the solution was evaporated under reduced pressure to remove methanol to give a pale brown syrupy residue.

The residue was dissolved in methylene chloride (50 ml) followed by washing with the 20% (w/v), and then  $Na_2CO_3$  solution, (20 ml, two times), and finally water (15 ml, two times). The organic layer was separated, dried over anhydrous magnesium sulfate, and filtered. After solvent evaporation to dryness under reduced pressure, a pale yellow syrupy residue was obtained. This residue was subjected to flash chromatography over silica (Solvent I) to give 78 (650 mg), in 74% yield as a mixture of  $\alpha$  and  $\beta$  anomers, and a small amount of 79 (95 mg) after solvent evaporation. Compound 78 was collected at

earlier fraction and gave white amorphous solids after recrystallization from a solution of ether and petroleum (7:3 v/v), m.p. = 94-95°C. The 79 was eluted out at latter fraction and collected after solvent evaporation. The recrystallization of 79 from a solution of methylene chloride and ether (10:1, v/v) gave white needles. Compound 79 was converted to 78 almost quantitatively in absolute methanol at pH = 3.

Further preparative layer chromatography over silica gel (Solvent J) of 78 gave two anomers, 82 (Rf = 0.65) and 83 (Rf = 0.55). Both of them gave amorphous solids from a solution of ether and petroleum ether (5:1, v/v), and were unequivocally assigned to  $\alpha$ -82 and  $\beta$ -83 glycosides respectively by analysis of their p.m.r. spectra. The melting point and spectroscopic data for  $\alpha$  anomer 82:

m.p. = 75-80°C

i.r. (cm<sup>-1</sup>), Fig. 14A:

3450 (OH stretching), 1670 (-CONH-), 1520 (aromatic skeleton),

p.m.r. (ppm), Fig. 14B:

1.19 (d, 3H, J = 6.3 Hz, CH<sub>3</sub>), 1.55 (q, 1H, H<sub>4a</sub>, J<sub>4a,4e</sub> = 12 Hz), 1.75 (broad doublet, 1H, H<sub>4e</sub>, J<sub>4e,4a</sub> = 16 Hz), 1.85 (dd, 2H, H<sub>2a</sub> and H<sub>2e</sub>), 2.71 (m, 1H, W<sub>H</sub> = 28 Hz, H<sub>3a</sub>), 3.34 (s, 3H, C<sub>1</sub>-OCH<sub>3</sub>), 3.85 (m, 1H, C<sub>5</sub>-H), 4.43 (d, 2H, two benzylic protons, J = 6 Hz), 4.80 (broad singlet, 1H, W<sub>H</sub> = 6 Hz, C<sub>1</sub>-H<sub>e</sub>), 5.77 (s, broad, 1H, NH), 7.30 (m, 5H, five aromatic protons).

Mass spectrum (M<sup>+</sup>/z), Fig. 14C:

263 (molecular ion), 248 (M-15), 232 (M-OCH<sub>3</sub>), 160, 106 (NH-CH<sub>2</sub>-Ph), 97, 91 (CH<sub>2</sub>Ph, 100%).

The melting point and spectroscopic data for  $\beta$  anomer 83:  
m.p. = 117-120 °C.

i.r. ( $\text{cm}^{-1}$ ), Fig. 15A:

3450 (NH stretching), 1680 (-CONH-), 1520 (aromatic C = C stretching and amide II band), 1020, 1080 (C-O-C and C-N-C bending vibration).

p.m.r. (ppm), Fig. 15B:

1.28 (d, 3H,  $\text{C}_5\text{-CH}_3$ ,  $J = 6.2$  Hz), 1.45 (q, 1H,  $\text{H}_{4a}$ ,  $J_{4a,4e} = 12$  Hz), 1.55 (q, 1H,  $\text{H}_{4e}$ ,  $J_{4e,4a} = 12$  Hz), 1.80 (broad d, 1H,  $\text{C}_2\text{-H}_a$ ,  $J_{2a,2e} = 11$  Hz), 2.00 (d, broad, 1H,  $\text{C}_2\text{-H}_e$ ,  $J_{2e,2a} = 11$  Hz), 2.45 (m, 1H,  $\text{C}_3\text{-H}_a$ ,  $\text{Wh} = 26$  Hz), 3.50 (s, 3H,  $\text{C}_1\text{-OCH}_3$ ), 3.55 (m, 1H,  $\text{C}_5\text{-H}$ ,  $J = 6.2$  Hz), 4.33 (dd, 1H,  $\text{C}_1\text{-H}_a$ ,  $\text{Wh} = 9$  Hz), 4.45 (d, 2H, two benzylic protons,  $J = 6$  Hz), 5.70 (s, broad, 1H, NH), 7.25 (m, 5H, five aromatic protons).

Mass Spectra (M/z), Fig. 15C:

263 (molecular ion), 248 (M-Me), 231 (M- $\text{CH}_3\text{OH}$ ), 106 (NH $\text{CH}_2\text{Ph}$ ), 97, 91 ( $\text{CH}_2\text{Ph}$ , 100%).

High resolution mass spectrum ( $\text{M}^+/\text{z}$ ), Fig. 15D:

$\text{C}_{14}\text{H}_{17}\text{N}_1\text{O}_2$ : calculated 231.1259328, observed 231.1267090;  
 $\text{C}_7\text{H}_8\text{N}_1$ : calculated 106.0656760, observed: 106.0681000;  $\text{C}_7\text{H}_7$ :  
calculated 91.0547764, observed: 91.0543820.

The melting point and spectroscopic data for 79 (mixture of two anomers):

m.p = 155-157 °C

i.r. ( $\text{cm}^{-1}$ ), Fig. 16A :

3570 (OH), 3450 (NH), 1680 ( -CONH-), 1520 (benzine ring )

p.m.r. (ppm), Fig. 16B: (referable to Figs. 14B and 15B)  
Mass Spectrum ( $M^+/e$ ), Fig. 16C:  
249 (molecular ion), 231 (M-18), 149, 106, 91 (100%, tropylium ion).

#### CONVERSION OF 3-N-(BENZYL-CARBOXAMIDO)-2,3,4,6-TETRA- DEOXY-DL-THREO-HEXOPYRANOSE (79) TO 78

To the stirred solution of 200 mg of 79 in absolute methanol (100 ml) was bubbled anhydrous hydrogen chloride gas until pH 3, through a gas dispersion tube, at 0 C. The solution was stirred under this condition for 3 hr. The usual work up gave a white amorphous crystal (203 mg), in 96 % yield. Its physical and spectroscopic properties are identical to those of 78.

#### PREPARATION OF METHYL 3-(N-BENZYL-CARBOXAMIDO)-2,3,4,6- TETRADEOXY-DL-ERYTHRO-HEXOPYRANOSE (80) AND THE TWO ANOMERS 84 AND 85

To the solution of absolute methanol (100 ml) and 2-allyl-N-benzyl-4-hydroxy-pentanamide (77) (1 g) was passed dry ozone through a gas dispersion tube with stirring at -20 to -25 C. After 15 minutes, the reaction was completed as judged by t.l.c. (Solvent A). During t.l.c., dry nitrogen gas was bubbled into the reaction solution to prevent further ozonolysis temporarily.

The 2 ml of trimethyl phosphite [ $P(OCH_3)_3$ ] was added into the reaction solution. The solution was heated to reflux with a stirring

for additional 15 hr, and then evaporated under reduced pressure to remove methanol. The residue was dissolved in methylene chloride (50 ml) followed by washing with 20% sodium carbonate solution (20 ml, two times) and water (15 ml, two times). The organic solution was separated and dried over anhydrous magnesium sulfate followed by filtration. The filtrate was evaporated to dryness under reduced pressure to give a pale yellow syrup. The flash column chromatography (Solvent K) of this syrupy gave 80 (520 mg) in 70% yield, and as white amorphous solids from solution of ether and petroleum (7:3, v/v), m.p. = 57 - 59 °C.

Further preparative layer chromatography of 80 over silica gel (Solvent J) gave two anomers, 84 (Rf = 0.65) and 85 (Rf = 0.5) and both as white amorphous solids from a solution of ether and petroleum ether (v/v 5:1) with m.p. = 57-58 °C and m.p. = 55-56 °C respectively. They were unambiguously assigned to  $\beta$ -84 and  $\alpha$ -85 glycosides respectively by analysis of their p.m.r. spectra. The melting point and spectroscopic data for  $\beta$  anomer 84:

m.p. = 57-58 °C

i.r. (cm<sup>-1</sup>), Fig. 17A:

3450 (NH), 1670 (-CONH-, stretching), 1520 (aromatic C=C bending and the amide II band), 1050 (-NH-C- bending).

p.m.r. (ppm), Fig. 17B:

1.21 (d, 3H, J = 6.2 Hz, C<sub>5</sub>-CH<sub>3</sub>), 1.45 (m, 1H, C<sub>4</sub>-H<sub>a</sub>), 1.80 (broad doublet, 1H, C<sub>4</sub>-H<sub>e</sub>, J<sub>4e,4a</sub> = 14 Hz), 1.56 (m, 1H, C<sub>2</sub>-H<sub>a</sub>), 1.90 (broad d, 1H, C<sub>2</sub>-H<sub>e</sub>, J<sub>HeHa</sub> = 12 Hz), 2.72 (m, 1H, C<sub>3</sub>-H<sub>e</sub>, Wh = 13.5 Hz), 3.43 (s, 3H, C<sub>1</sub>-OCH<sub>3</sub>), 3.98 (m, 1H, C<sub>5</sub>-H), 4.37 (d,

2H, benzylic protons,  $J = 5.4$  Hz), 4.76 (dd, 1H,  $W_h = 8.5$  Hz,  $C_1-H_a$ ), 6.20 (s, broad, 1H, NH), 7.30 (m, 5H, aromatic hydrogens).

Mass Spectra ( $M^+/z$ ), Fig. 17C:

91 (tropylium ion), 97 (27%), 106 (NHCH<sub>2</sub>Ph), 157 (100%), 162 (47%), 231 (M-CH<sub>3</sub>OH), 262 (M-1), 263 (molecular ion).

High resolution Mass spectrum ( $M^+/z$ ), Fig. 17D:

$C_{15}H_{21}O_3N_1$ : calculated observed: 263.1527710.

The melting point and spectroscopic data for  $\alpha$  anomer 85:

m.p. = 55 - 56°C.

i.r. (cm<sup>-1</sup>), Fig. 18A:

3450 (free hydrogen bonding NH stretching), 3310 (intramolecular hydrogen bonding NH stretching), 1660 (-CONH-), 1560 (benzene ring skeleton and amide II), 1520, 1050 (-NH-C-).

p.m.r. (ppm), Fig. 18B:

1.14 (d, 3H, C<sub>5</sub>-CH<sub>3</sub>,  $J = 6.2$  Hz), 1.55 (m, 1H, C<sub>4</sub>-H<sub>a</sub>), 2.05 (broad doublet, 1H, C<sub>4</sub>-H<sub>e</sub>), 1.97 (poor t, 2H, C<sub>2</sub>-H<sub>a</sub> and C<sub>2</sub>-H<sub>e</sub>), 2.73 (m, 1H, C<sub>3</sub>-H<sub>e</sub>,  $W_h = 11$  Hz), 3.18 (s, 3H, C<sub>1</sub>-OCH<sub>3</sub>), 3.80 (m, 1H, C<sub>5</sub>-H), 4.40 (d, 2H, two benzylic protons), 4.70 (d, 1H, C<sub>1</sub>-H<sub>a</sub>,  $W_h = 7.5$  Hz), 7.30 (m, 5H, five aromatic protons), 7.85 (s, broad, 1H, NH).

Mass Spectra (M/z), Fig. 18C:

91 (100%, tropylium ion), 97 (97%), 106 (NHCH<sub>2</sub>Ph), 162, 231 (M-MeOH).

High resolution Mass spectrum ( $M^+/z$ ), Fig. 18D:

$C_{14}H_{17}O_2N_1$ : calculated 231.1259328; observed 231.1255950.

PREPARATION OF METHYL 3-(N-BENZYLAMINO-METHYL)-2,3,4,6-TETRADEOXY-DL-THREO-HEXOPYRANOSE (86) AND THE TWO ANOMERS 88 AND 89

To the solution of anhydrous tetrahydrofuran (THF) (50 ml) and lithium aluminium hydride (80 mg) was added 86 (100 mg) at 0°C. After being stirred for 20 min at 0°C, the reaction solution was heated to 50°C and stirred for additional 15 hr. The solution was cooled to room temperature followed by adding water (30 ml), and then stirred at room temperature for 40 min. The solution was filtered to remove some aluminium hydroxide residue evolved in the reaction. The filtrate was evaporate to reduce the total volume of the solution to about 30 ml. Then it was extracted with methylene chloride (20 ml, two times) exhaustively. The combined extract was dried over anhydrous magnesium sulfate, filtered and evaporated to dryness to give a syrupy residue. The flash column chromatography of the residue over silica gave 86 (70 mg), as a colourless syrup. The yield was 74%. The further preparative layer chromatography of 86 upon silica gel (Solvent M) gave two anomers, 88 (Rf = 0.26) and 89 (Rf = 0.17), which are assigned to  $\alpha$  and  $\beta$  anomer respectively. The spectroscopic data for  $\alpha$  anomer 88:

i.r. ( $\text{cm}^{-1}$ ), Fig. 19A:

2850 ( $-\text{OCH}_3$ ), 1130 (C-O-C), 1060.

p.m.r. (ppm), Fig. 19B:

1.16 (d, 3H,  $-\text{CH}_3$ ), 1.75 (m, 5H,  $\text{C}_4\text{-H}_a\text{H}_e$ ,  $\text{C}_2\text{-H}_a\text{H}_e$  and  $\text{C}_3\text{-H}_a$ ),  
2.10 (broad s, 1H, NH), 2.45 (t. 2H,  $\text{CH}_2\text{-N-}$ ), 3.34 (s, 3H,  $-\text{OCH}_3$ ),

3.76 (s, 2H, two benzylic protons), 3.85 (m, 1H, C<sub>5</sub>-H<sub>a</sub>), 4.75 (d, 1H, C<sub>1</sub>-H<sub>e</sub>), 7.34 (m, 5H, five aromatic protons).

Mass spectrum (M<sup>+</sup>/z), Fig. 19C:

250 (M+1), 234 (M-CH<sub>3</sub>), 218 (M-OCH<sub>3</sub>), 120 (CH<sub>2</sub>NHCH<sub>2</sub>Ph), 91 (CH<sub>2</sub>Ph, 100%).

The spectroscopic data for  $\beta$  isomer 89:

i.r. (cm<sup>-1</sup>), Fig. 20A:

2850 (-OCH<sub>3</sub>), 1390, 1130, 1080 (-C-O-C-), 1000.

p.m.r. (ppm), Fig. 20B:

1.24 (d, 3H, -CH<sub>3</sub>), 1.75 (m, 6H, C<sub>2</sub>-H<sub>a</sub>H<sub>e</sub>, C<sub>4</sub>-H<sub>a</sub>H<sub>e</sub>, C<sub>3</sub>-H<sub>a</sub> and NH), 2.55 (d, 2H, two methylene protons, C-CH<sub>2</sub>-N-), 3.48 (s, 3H, -OCH<sub>3</sub>), 3.55 (m, 1H, C<sub>5</sub>-H<sub>a</sub>), 3.79 (s, 2H, two benzylic protons-CH<sub>2</sub>-Ph), 4.35 (dd, 1H, C<sub>1</sub>-H<sub>a</sub>), 7.35 (m, 5H, five aromatic protons).

Mass spectrum (M<sup>+</sup>/z), Fig. 20C:

249 (molecular ion), 248 (M-H), 234 (M-CH<sub>3</sub>), 120 (CH<sub>2</sub>NHCH<sub>2</sub>Ph), 91 (tropylium ion, 100 %).

High resolution Mass spectrum (M<sup>+</sup>/z), Fig. 20D:

C<sub>15</sub>H<sub>23</sub>O<sub>2</sub>N<sub>1</sub>: calculated 249.1728840, observed, 249.1675870;

C<sub>14</sub>H<sub>20</sub>O<sub>2</sub>N<sub>1</sub>: calculated 234.1494084, observed 234.1481020;

C<sub>8</sub>H<sub>10</sub>N<sub>1</sub>: calculated 120.0813264, observed 120.0804290.

PREPARATION OF METHYL 3-N-(BENZYLAMINO-METHYL)-2,3,4,6-TETRADEOXY-DL-ERYTHRO-HEXOPYRANOSE (87) AND THE TWO ANOMER 90 AND 91

Compound 80 (150 mg) was placed into stirred the solution of tetrahydrofuran (50 ml) and lithium aluminium hydride (80 mg) at 0 °C. After being stirred for 20 min at 0 °C, the solution was heated to 50 °C and stirred for 3hr. Then the solution was cooled to room temperature and stirred for additional 15 hr. The solution was cooled to 0 °C followed by water addition (30 ml) and stirred for 30 min, then filtered. The filtrate was evaporated under reduced pressure to reduce total volume to about 40 ml and was extracted with methylene chloride (20 ml, two times). The extract was dried over anhydrous magnesium sulfate, filtered and evaporated to dryness to give a colourless syrupy residue. The flash chromatography of the syrupy residue over silica gave 87 (92 mg), as a colourless syrup, in 64.7 %. Preparative layer chromatography of 87 over silica gel gave 90 ( $R_f = 0.3$ ) and 91 ( $R_f = 0.25$ ), as a pair of anomers, with  $\beta$  and  $\alpha$  glycosidic bond respectively.

The spectroscopic data for  $\beta$  isomer 90:

i.r. ( $\text{cm}^{-1}$ ), Fig. 21A:

3050 (weak shoulder, aromatic C-H), 2850 ( $-\text{OCH}_3$ ), 1050 (tense,  $-\text{NH}-\text{C}-$ ), 1000.

p.m.r. (ppm), Fig. 21B:

1.25 (d, 3H,  $-\text{CH}_3$ ,  $J = 6$  Hz), 1.50 to 1.70 (m, 5H,  $\text{C}_4-\text{H}_a\text{H}_e$ ,  $\text{C}_2-\text{H}_a\text{H}_e$  and NH), 2.15 (m, 1H,  $\text{C}_3-\text{H}_e$ ), 2.65 (d, 2H,  $\text{CH}_2-\text{N}$ ), 3.44 (s, 3H,  $\text{CH}_3\text{O}$ ), 3.81 (s, 2H, two benzylic hydrogens), 3.75 (m, 1H,  $\text{C}_4-\text{H}$ ), 4.50 (dd, 1H,  $\text{C}_1-\text{H}_a$ ,  $W_h = 7.5$  Hz), 7.30 (m, 5H, aromatic protons).

Mass spectrum ( $M^+/z$ ), Fig. 21C:

249 (molecular ion), 234 (M-CH<sub>3</sub>), 218 (M-OCH<sub>3</sub>), 120 (CH<sub>2</sub>NH-CH<sub>2</sub>Ph), 106 (NHCH<sub>2</sub>Ph), 91 (CH<sub>2</sub>Ph, 100%)

High resolution mass spectrum, (M<sup>+</sup>/z), Fig. 21D:

C<sub>15</sub>H<sub>23</sub>N<sub>1</sub>O<sub>2</sub>: calculated 249.1728840, observed 249.1718140;

C<sub>14</sub>H<sub>20</sub>N<sub>1</sub>O<sub>2</sub>: calculated 234.1494084, observed, 234.1515660;

C<sub>14</sub>H<sub>20</sub>N<sub>1</sub>O<sub>1</sub>: calculated 218.1544934, observed, 218.1544340;

C<sub>7</sub>H<sub>8</sub>N<sub>1</sub>: calculated 106.0629970, observed 106.0650330;

C<sub>8</sub>H<sub>10</sub>N<sub>1</sub>: calculated 120.0796360, observed 120.0796360;

C<sub>7</sub>H<sub>7</sub>: calculated 91.0547764, observed 91.0530090.

The spectroscopic data for  $\alpha$ anomer 91:

i.r. (cm<sup>-1</sup>), Fig. 22A:

3050 (weak shoulder, benzene), 2850 (-OCH<sub>3</sub>), 1120, 1050 (C-O-C).

p.m.r. (ppm), Fig. 22B:

1.15 (d, 3H, -CH<sub>3</sub>), 1.45-1.85 (m, 5H, C<sub>4</sub>-H<sub>a</sub>H<sub>e</sub>, C<sub>2</sub>-H<sub>a</sub>H<sub>e</sub> and NH),  
1.95 (m, 1H, NH), 2.80 (t, 2H, -CH<sub>2</sub>-N-), 3.31 (s, 3H, -OCH<sub>3</sub>), 3.80  
(s, 2H, two benzylic protons), 3.95 (m, 1H, C<sub>5</sub>-H<sub>a</sub>), 4.65 (broad s,  
1H, C<sub>1</sub>-H<sub>e</sub>), 7.30 (m, 5H, five aromatic hydrogens).

Mass spectrum (M<sup>+</sup>/z), Fig. 22C:

249 (molecular ion), 234 (M-CH<sub>3</sub>), 218 (M-OCH<sub>3</sub>), 120 (CH<sub>2</sub>NH-CH<sub>2</sub>Ph), 91 (CH<sub>2</sub>Ph, 100%).

## SPECTRA

All melting points were recorded on a Fischer-Johns melting point apparatus and were uncorrected. Infrared spectra were taken on a Perkin Elmer Infracord 710 spectrometer, using sodium chloride cell with methylene chloride as a solvent. Mass spectra were recorded on a V.G.7070EHF mass spectrometer with a 70 FAB system. A Bruker AM-300 spectrometer was used to make all p.m.r. spectra and  $^{13}\text{C}$  n.m.r. spectrum with  $\text{CDCl}_3$  as a solvent and tetramethylsilane (TMS) as an internal reference except those presented in figs. 8A, 10B, 11B, which were made on a Varian EM-360 spectrometer.




Fig. 1A I. r. Spectrum of Aklavinone (55)






Fig. 1B-2 The Double Irradiation P. m. r. Spectrum of Aklavinone (55):a) The Double Irradiation Applied on the H<sub>7</sub>-H, at  $\delta = 5.38$  ppm; b) The Double Irradiation Applied on the H<sub>10</sub>-H, at  $\delta = 4.13$  ppm.




Fig. 2A I. r. Spectrum of 1,4-Di-O-(p-nitrobenzoyl)-3-N-trifluoroacetyl-daunosamine (54)




Fig. 2B P. m. r. Spectrum of 1,4-Di-O-(p-Nitrobenzoyl)-3-N-trifluoroacetyl-daunosamine (54)




Fig. 3A I.r. Spectrum of Methyl 4-O-(p-nitrobenzoyl)-3-N-trifluoroacetyl-daunosamine (46)



YAN40611.001  
 AU PROG:  
 AUTOM41F  
 DATE 28-3-88

11.32  
 11.32  
 11.32

6.2600

3.4130

1.11  
 1.11  
 1.11

YAN-406-1 1-H AT 300 MHZ IN CDCL3

SF 300.133  
 CY 112.350000  
 Q1 3390.000  
 S1 32788  
 ID 32788  
 SM 5000.000  
 HZ/PT .305  
 PM 6.0  
 RD 4.000  
 AQ 3.277  
 RG 200  
 NS 32  
 TE 300  
 FM 6300  
 F2 3205.000  
 DP 60L D0

LB 1.00  
 GB 1.600  
 CX 7.100  
 CY 8.80  
 F1 8.296P  
 F2 8.249P  
 HZ/CM 4.391  
 PPM/CM 1.250  
 SR 33H 7.42






Fig. 3B P.m.r. Spectrum of Methyl 4-O-(p-nitrobenzoyl)-3-N-trifluoroacetyl- $\alpha$ -daunosamine (47)

YH4861028 A1 BQ=2 25.00K-08 11 d. d. d. 08 53 JMH  
 QM=0 I=1.4v Ha=0 TIC=45279008 Recl  
 P1= 0° Cal B

HNR 9401000  
 HRS 150



**Fig. 3C**  
**Mass Spectrum of Methyl 4-O-(p-nitrobenzoyl)-3-N-**  
**trifluoroacetyl- $\alpha$ -daunosamine (47)**

B  
 J  
 I  
 E  
 R  
 YAN4062.001  
 AU PROG  
 AUTOH1 B1  
 DATE 28-3-88  
 PPH  
 4.986  
 4.971  
 4.956  
 4.941  
 4.926  
 4.911  
 4.896  
 4.881  
 4.866  
 4.851  
 4.836  
 4.821  
 4.806  
 4.791  
 4.776  
 4.761  
 4.746  
 4.731  
 4.716  
 4.701  
 4.686  
 4.671  
 4.656  
 4.641  
 4.626  
 4.611  
 4.596  
 4.581  
 4.566  
 4.551  
 4.536  
 4.521  
 4.506  
 4.491  
 4.476  
 4.461  
 4.446  
 4.431  
 4.416  
 4.401  
 4.386  
 4.371  
 4.356  
 4.341  
 4.326  
 4.311  
 4.296  
 4.281  
 4.266  
 4.251  
 4.236  
 4.221  
 4.206  
 4.191  
 4.176  
 4.161  
 4.146  
 4.131  
 4.116  
 4.101  
 4.086  
 4.071  
 4.056  
 4.041  
 4.026  
 4.011  
 3.996  
 3.981  
 3.966  
 3.951  
 3.936  
 3.921  
 3.906  
 3.891  
 3.876  
 3.861  
 3.846  
 3.831  
 3.816  
 3.801  
 3.786  
 3.771  
 3.756  
 3.741  
 3.726  
 3.711  
 3.696  
 3.681  
 3.666  
 3.651  
 3.636  
 3.621  
 3.606  
 3.591  
 3.576  
 3.561  
 3.546  
 3.531  
 3.516  
 3.501  
 3.486  
 3.471  
 3.456  
 3.441  
 3.426  
 3.411  
 3.396  
 3.381  
 3.366  
 3.351  
 3.336  
 3.321  
 3.306  
 3.291  
 3.276  
 3.261  
 3.246  
 3.231  
 3.216  
 3.201  
 3.186  
 3.171  
 3.156  
 3.141  
 3.126  
 3.111  
 3.096  
 3.081  
 3.066  
 3.051  
 3.036  
 3.021  
 3.006  
 2.991  
 2.976  
 2.961  
 2.946  
 2.931  
 2.916  
 2.901  
 2.886  
 2.871  
 2.856  
 2.841  
 2.826  
 2.811  
 2.796  
 2.781  
 2.766  
 2.751  
 2.736  
 2.721  
 2.706  
 2.691  
 2.676  
 2.661  
 2.646  
 2.631  
 2.616  
 2.601  
 2.586  
 2.571  
 2.556  
 2.541  
 2.526  
 2.511  
 2.496  
 2.481  
 2.466  
 2.451  
 2.436  
 2.421  
 2.406  
 2.391  
 2.376  
 2.361  
 2.346  
 2.331  
 2.316  
 2.301  
 2.286  
 2.271  
 2.256  
 2.241  
 2.226  
 2.211  
 2.196  
 2.181  
 2.166  
 2.151  
 2.136  
 2.121  
 2.106  
 2.091  
 2.076  
 2.061  
 2.046  
 2.031  
 2.016  
 2.001  
 1.986  
 1.971  
 1.956  
 1.941  
 1.926  
 1.911  
 1.896  
 1.881  
 1.866  
 1.851  
 1.836  
 1.821  
 1.806  
 1.791  
 1.776  
 1.761  
 1.746  
 1.731  
 1.716  
 1.701  
 1.686  
 1.671  
 1.656  
 1.641  
 1.626  
 1.611  
 1.596  
 1.581  
 1.566  
 1.551  
 1.536  
 1.521  
 1.506  
 1.491  
 1.476  
 1.461  
 1.446  
 1.431  
 1.416  
 1.401  
 1.386  
 1.371  
 1.356  
 1.341  
 1.326  
 1.311  
 1.296  
 1.281  
 1.266  
 1.251  
 1.236  
 1.221  
 1.206  
 1.191  
 1.176  
 1.161  
 1.146  
 1.131  
 1.116  
 1.101  
 1.086  
 1.071  
 1.056  
 1.041  
 1.026  
 1.011  
 0.996  
 0.981  
 0.966  
 0.951  
 0.936  
 0.921  
 0.906  
 0.891  
 0.876  
 0.861  
 0.846  
 0.831  
 0.816  
 0.801  
 0.786  
 0.771  
 0.756  
 0.741  
 0.726  
 0.711  
 0.696  
 0.681  
 0.666  
 0.651  
 0.636  
 0.621  
 0.606  
 0.591  
 0.576  
 0.561  
 0.546  
 0.531  
 0.516  
 0.501  
 0.486  
 0.471  
 0.456  
 0.441  
 0.426  
 0.411  
 0.396  
 0.381  
 0.366  
 0.351  
 0.336  
 0.321  
 0.306  
 0.291  
 0.276  
 0.261  
 0.246  
 0.231  
 0.216  
 0.201  
 0.186  
 0.171  
 0.156  
 0.141  
 0.126  
 0.111  
 0.096  
 0.081  
 0.066  
 0.051  
 0.036  
 0.021  
 0.006  
 0.001

SF 300.133  
 SY 112.3500000  
 O1 5500.000  
 SI 32768  
 TD 32768  
 SM 5000.000  
 HZ/PT .305  
 PM 6.0  
 RD 4.000  
 AG 3.277  
 RS 200  
 NS 32  
 TE 300  
 FH 6300  
 OZ 3205.000  
 DP 60L D0  
 LB .100  
 GB 37.600  
 CX 18.500  
 CY 8.996P  
 F1 .249P  
 F2 74.991  
 PPM/CM .250  
 SR 3367.42





Fig. 4B  
 P.M.R. Spectrum of Methyl 4-O-(p-nitrobenzoyl)-3-N-  
 trifluoroacetyl- $\beta$ -daunosamine (48)




Fig. 4C Mass Spectrum of Methyl 4-O-(p-nitrobenzoyl)-β-D-ribofuranoside-3-N-trifluoroacetate (48)





Fig. 5A L. r. Spectrum of 7-O-[3'-N-Trifluoroacetyl]-4'-O-(p-nitrobenzoyl)- $\alpha$ -daunosaminyl]-aklavinone (56)



Regular Broad Band Decoupling




Fig. 5B-2 <sup>13</sup>C N. m. r. Spectrum of 7-O-[3'-N-Trifluoroacetyl-4'-O-(p-nitrobenzoyl)-α-daunosaminyl]-β-aklavinone (56)




Fig. 6A I. r. Spectrum of 7-O-[3'-N-Trifluoroacetyl]-4'-O-(p-nitrobenzoyl)-β-D-aunosaminyll-aklavinone (57)





Fig. 6B P. m. r. Spectrum of 7-O-[3'-N-Trifluoroacetyl-4'-  
O-(p-nitrobenzoyl)-β-daunosaminyl]-aklavinone (57)




Fig. 8A I. r. Spectrum of 2, 2-Diallyl-ethylmalonate (64)




Fig. 8B P. m. r. Spectrum of 2, 2-Diallyl-ethylmalonate (64)





Fig. 9A I. r. Spectrum of 2, 2-Diallyl-malonic acid (65)

Fig. 9B P. m. r. Spectrum of 2, 2-Diallyl-malonic acid (65)



S1840109 x1 80d=69 15-FLB-BB 11 3-8 02 25 /M/H/ L1  
 09H=125 TIC=719558976  
 RCT MASS  
 21.0  
 Front: PT= 0° Sys: RCHLD15  
 Cal: S184

HR: 65534000  
 MASS: 125.020

AUTOREPORT




Fig. 9C Mass Spectrum of 2, 2-Diallyl-malonic acid (65)




Fig. 10A I. r. Spectrum of 2-Allyl-4-pentenoic acid (66)




Fig. 10B P. m. r. Spectrum of 2-Allyl-4-pentenoic acid (66)

YV1400212 x1 Bg0:190 20 JUN 87 12:38:00 45 50 /ALIN LI  
 60N=0 1-2.5v Ha=0 TIC=62735000 Acnt UOM Sys LR  
 Text: RES 1450 \*x1.0 Cal: HCRAL





Fig. 10C Mass Spectrum of 2-Allyl-4-pentenoic acid (66)

HMR:  
 MASS:




Fig. 11A I. r. Spectrum of 2-Allyl-4-methyl- $\gamma$ -butyrolactone (67)




Fig. 11B P. m. r. Spectrum of 2-Allyl-4-methyl- $\gamma$ -butyrolactone (67)




Fig. 11C Mass Spectrum of 2-Allyl-4-methyl- $\gamma$ -butyrolactone (67)

YAN3#17 x1 Bgd=1 4-NOV-86 08:58:03:13 70E-HF EI+  
 BpM=81 I=9.0u Hw=231 TIC=402916992 Acnt: UDM Sys: EI  
 Text: HI-RESOLUTION DBE OBS: NRSS PT=0 Cal: YAN3  
 M/E C H O MMU DBE OBS: NRSS  
 12

140 8 12 2 -0.5 3.0 140.0842440






Fig. 11D High Resolution Mass Spectrum of 2-Allyl-4-methyl-γ-butyrolactone (67)

Fig. 12A I. r. Spectrum of (R,S) 2-allyl-4-hydroxy-N-benzyl-erythro-pentanamide (75)





PPM

YAN157U.001  
AU PROG:  
AUTOM1  
DATE 22-1-86

|        |          |
|--------|----------|
| SF     | 300.133  |
| SY     | 112.350  |
| O1     | 5500.000 |
| SI     | 32768    |
| TD     | 32768    |
| SM     | 3000.000 |
| HZ/PT  | .305     |
| PM     | 6.0      |
| RD     | 4.000    |
| AG     | 3.277    |
| RG     | 80       |
| NS     | 32       |
| TE     | 300      |
| FM     | 6300     |
| O2     | 3205.000 |
| DP     | 60L D0   |
| LB     | .100     |
| GB     | .600     |
| CX     | 37.00    |
| CY     | 18.50    |
| F1     | 9.103P   |
| F2     | -1.141P  |
| HZ/CM  | 74.981   |
| PPM/CM | 1.250    |
| SR     | 3367.42  |

7.3282  
7.3109  
7.2917  
7.2845  
7.2722  
7.2691  
7.2600

5.2976  
5.1066  
5.0494  
5.0455

4.4824  
4.4631  
4.4320  
4.4134

1.9773  
1.9620

1.5740

1.1987  
1.1782

1-H AT 300 MHZ. CDCL3





Fig. 12B P. m. r. Spectrum of (R,S) 2-Allyl-4-hydroxy-N-benzyl-erythro-pentanamide (75)

YHR247016 x1 800=10 16-DEC-87 14:30:00.41 70EHR EI+  
 Rpt=0 I=3.6v Ha=0 TIC=163245000 Acnt:HE Sg:LRD015  
 L0 RES PI=0° Cal:HCRL  
 \*x1.0

HHR: 23297000  
 HRS: 91





Fig. 12C Mass Spectrum of (R,S) 2-Allyl-4-hydroxy-N-benzyl-  
 erythro-pentanamide (75)




Fig. 13A I. r. Spectrum of (R,S) 2-Allyl-4-hydroxy-N-benzyl-threo-pentanamide (77)

\*X5.0\*

HRR: 23350000  
MSS: 91.063  
\*X5.0\*





Fig. 13C Mass Spectrum of (R,S) 2-Allyl-4-hydroxy-N-benzyl-threo-pentanamide (77)




Fig. 14A I.r. Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
2,3,4,6-O-DL-threo-hexopyranose (82)

BRUNNEN  
PPM

YAN263UP.001  
AU PROG:  
AUTOH1  
DATE 21-12-87

SF 300.133  
SY 112.3500000  
Q1 35500.000  
Q2 32728  
Q3 32728  
Q4 32728  
Q5 3000.000  
H2/P1 .305

PM 6.0  
RD 4.000  
AQ 3.277  
RG 10  
NS 32  
TE 300  
FM 6300  
D2 3205.000  
DP 601.00

LB 100  
GB 600  
CX 37.00  
CY 18.80  
F1 9.996P  
F2 9.996P  
H2/CH 74.951  
PPM/CH 74.951  
SR 3367.42

06.000  
06.000  
06.000  
06.000  
06.000  
06.000  
06.000  
06.000  
06.000  
06.000

4.4180  
4.4001

3.3320

1.8437  
1.8233  
1.8134

1.1926  
1.1716

0.712




Fig. 14B P.m.r. Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
2,3,4,6-O-DL-threo-hexopyranose (82)

YAN-263-UP 1-H AT 300 MHZ IN CDCL3

YMK6300127 x1 BqD=27 18-DEC-87 11:24:03 26 /ALH  
 BqF=0 I=2.7v Mw=0 TIC=188624888 Acnt:ME  
 PI=90 Sps:LRDLS  
 Cal:ICPL

HHR: 17455808  
 HSS: 91

AUTOREPOR





Fig. 14C Mass Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
 2,3,4,6- $\alpha$ -D-threo-hexopyranose (82)




Fig. 15A I.r. Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
2,3,4,6-tetra-deoxy-β-DL-threo-hexopyranose (83)

B  
L  
U  
E  
P  
P  
H

YAN263DN.001  
AU PH06:  
AUTOM1  
DATE 21-12-87

SF 300.133  
SY 112.350000  
O1 5500.000  
SI 32768  
TD 32768  
SM 5000.000  
HZ/PT .305

PH 5.0  
RD 4.000  
AG 3.277  
RG 64  
NS 32  
TE 300

FM 6300  
O2 3205.000  
DP 60L D0

LB .100  
GB 600  
CX 37.00  
CY 18.50  
F1 8.995P  
F2 .250P  
HZ/CM 74.991  
PPM/CM .250  
SR 3367.72

7.3368  
7.3128  
7.2605

YAN-263-DOWN 1-H AT 300 MHZIN CDCL3

4.4505  
4.4320

3.4924  
3.3459

2.1696

1.2889  
1.2683  
1.2033  
1.1824





Fig. 15B P.m.r. Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
2,3,4,6-tetra-deoxy-beta-DI-threo-hexopyranose (83)






Fig. 16A I.r. Spectrum of 3-N-(benzyl-carboxamido)-2,3,4,6-tetraoxy-DL-threo-hexopyranose (79)



RRN1490110 x1 Bgd=22 18-DEC-87 11 1.0 03 02 7/8/87 L1.  
 Bgd=0 I=1.5v Ha=0 TIC=45594880 Runt: ME Sps: LREDIS  
 PT= 0<sup>o</sup> Cal: HCHL

HNR: 9883908  
 HRSS: 91




Fig. 16C Mass Spectrum of 3-N-(benzyl-carboxamido)-2,3,4,6-tetra-deoxy-DL-threo-hexopyranose (79)








Fig. 17A I.r. Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
2,3,4,6-tetra-deoxy-β-DL-erythro-hexopyranose (84)

6-11-68

EMULSION

PPM



YAN-11 1-H AT 300 MHZ IN CDCL3





Fig. 17B

P.m.r. Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
2,3,4,6-tetra-deoxy-beta-DL-erythro-hexopyranose (84)

VMR2334 X1 09d=19 15-DEC-07 11 2+0 01 07 70EHF EL+  
 BpH=0 I=1.4v Ha=0 TIC=113057000 Acct:NE Sys:LR015  
 L0 RES \*X1.0 PI=0° Cal:HCNL

HHR: 9007800  
 HRS: 157





Fig. 17C Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
 2,3,4,6-tetra-deoxy-beta-D-erythro-hexopyranose (84)




Fig. 18A

I.R. Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
2,3,4,6-tetra-deoxy- $\alpha$ -DL-erythro-hexopyranose (85)






Fig. 18B P.m.r. Spectrum of Methyl 3-N-(benzyl-carboxamido) -  
2,3,4,6-tetra-deoxy-α-DL-erythro-hexopyranose (85)

YMR2106 X1 900=1 15-DEC-92 11:10:08 08 25 70MHR EI\*  
 1-6.8v Ha=0 TIC=239517000 Acnt:HE P1=g<sup>o</sup> Sus:LRDIS  
 L0 RES \*X1.0 PI=g<sup>o</sup> Cal:MCAL

HHR: 4463988  
 HRS: 91





Fig. 18C Mass Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
 2,3,4,6-tetra-deoxy-α-DL-erythro-hexopyranose (85)

YRND#26 X1 Bgd=25 5-JAN-87 16:00:02:37 70EHF EI+  
 BpM=69 I=10v Hm=499 TIC=411628992 Acnt: Sys:ACMEDIS  
 ACC.MRSS PT=0° Cal:YRND  
 N/E C H O N MWU DBE OBS.MRSS  
 12

|     |    |    |   |   |      |     |             |
|-----|----|----|---|---|------|-----|-------------|
| 231 | 14 | 17 | 2 | 1 | 0.8  | 7.0 | 231.1251070 |
|     | 9  | 17 | 4 | 3 | -3.2 | 3.0 |             |





Fig. 18D High Resolution Mass Spectrum of Methyl 3-N-(benzyl-carboxamido)-2,3,4,6-tetra-deoxy-α-DL-erythro-hexopyranose (85)




Fig. 19A I.R. Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
2,3,4,6-tetra-deoxy- $\alpha$ -DL-threo-hexopyranose (88)


  
 BAKER INSTRUMENTS

YAN5.001  
 AU PROG:  
 AUTOM1  
 DATE 18-11-87

SF 300.133  
 SY 112.350000  
 O1 3550.000  
 S1 327.68  
 T1 327.68  
 S2 3000.000  
 H2/PT .305  
 PM 6.0  
 RD 4.000  
 AG 3.277  
 HS 4  
 NS 32  
 TE 300  
 FM 6300  
 O2 3205.000  
 DP 60L D0

7.436  
 7.434  
 7.432  
 7.430  
 7.428  
 7.426  
 7.424  
 7.422

YAN-5 1-H AT 300 MHZ IN CDCL3

9.7650  
 9.7610  
 3.4815  
 3.4785  
 3.4755  
 3.4725  
 3.4695

2.1576

1.2468  
 1.2453  
 1.2438  
 1.2423




Fig. 19B P.m.r. Spectrum of Methyl 3-N-(benzyl)-carboxamido)-  
 2,3,4,6-tetra-deoxy-α-DL-threo-hexopyranose (88)

NAME: 30076 X1 Bq4-21 4-FEB-80 15 5-0 02 11 20.14  
 DATE: 1-6-76 MS=0 TIC=133024000 Runt: ME Svs LRE(1)5  
 PI= 0° Cal: HCNL

\* 140.0

HMR 44869888  
 MASS: 91  
 140.0




Fig. 19C Mass Spectrum of Methyl 3-N-(benzyl-carboxamido)-  
 2,3,4,6-tetra-deoxy-0-DL-threo-hexopyranose (88)




Fig. 20A I.r. Spectrum of Methyl 3-N-(benzylamino-methyl)-  
2,3,4,6-tetraoxy-β-DL-threo-hexopyranose (89)

BRUKER  
PPM

FANR249D .001  
AU PRO6  
AUTOH1  
DATE 3-2-88

SF 300.133  
SY 112.3500000  
O1 5500.000  
S1 32758  
F0 32758  
S2 5000.000  
WZ/PT 305

24 6.0  
40 4.000  
46 100  
48 100  
NS 32  
TE 300

FM 6300  
G2 3205.000  
JP 60L D0  
AB 100  
CB 6.00  
CY 3/ CY  
F1 8.50  
F2 8.95P  
FZ/CM 74.991  
PPM/CM 250P  
SH 3167.72

7.331  
7.315  
7.299  
7.283

FAN-R-249-DOWN 1-11 AT 300 MHz IN 1.DX.L 1

3.7962  
3.4957  
3.2254

1.111  
1.095  
1.079  
1.063





Fig. 20B P.m.r. Spectrum of Methyl 3-N-(benzylamino-methyl) - 2,3,4,6-tetra-deoxy- $\beta$ -D-threo-hexopyranose (89)

YMR2450115 x1 Bq=3 4-TEB-00 15-0-0-00 40 20CHF E1+  
 Rp#-0 1-5.6v Ha=0 TIC=123094000 Acnt:ME Sps:LR015  
 PT=0<sup>0</sup> Cal:HCAL

\*x10<sup>-0</sup>

HMR 36307000  
 HRSS 91  
 x10<sup>-0</sup>




Fig. 20C



Mass Spectrum of Methyl 3-N-(benzylamino)-methyl)-  
 2,3,4,6-tetraoxy- $\beta$ -DL-threo-hexopyranose (89)

Fig. 20D


YAN249D#52 x1 Bgd=1 5-FEB-88 15:14:03:15 70EHF EI+  
 Bp#-69 I=10v H#-500 TIC=399312000 Acnt: Sys:ACMEDIS  
 ACC MASS PT= 0° Cal: YAN249D

M/E C H O N MU DBE OBS.MASS  
 12


| M/E | C  | H  | O | N | MU  | DBE | OBS.MASS    |
|-----|----|----|---|---|-----|-----|-------------|
| 249 | 15 | 23 | 2 | 1 | 5.3 | 5.0 | 249.1675870 |
| 120 | 8  | 18 | 0 | 1 | 8.9 | 4.5 | 120.8884290 |
| 234 | 14 | 20 | 2 | 1 | 1.3 | 5.5 | 234.1481020 |



#52 1  
 3470  
 1170  
 MASS (ACC)



MASS (ACC)



MASS (ACC)

High Resolution Mass Spectrum of Methyl 3-N-(benzylamino-methyl)-2,3,4,6-tetra-deoxy-β-DL-threo-hexopyranose (89)




Fig. 21A I.r. Spectrum of Methyl 3-N-(benzylamino)-methyl-  
2,3,4,6-tetra-deoxy-β-DL-erythro-hexopyranose (90)

BRUKER  
 88

YDR249U.001  
 AU PR05  
 AUTOM1  
 DATE 11-2-88

SF 300.133  
 SY 112.3500000  
 Q1 3500.000  
 S1 32.768  
 T0 32.768  
 SW 5000.000  
 HZ/P1 305  
 PW 6.0  
 R0 4.000  
 A0 3.277  
 R16 80  
 NS 32  
 TE 300  
 FM 6.100  
 UZ 3205.000  
 DP BOL D0

LB 100  
 GB 600  
 LX 37.00  
 LY 18.50  
 F1 8.996P  
 F2 249P  
 HZ/CM 74.991  
 PPM/CM 250  
 SR 3367.42

7.4  
 7.3  
 7.2  
 7.1




Fig. 21B P.m.r. Spectrum of Methyl 3-N-(benzylamino-methyl)-  
 2,3,4,6-tetra-deoxy-β-DL-erythro-hexopyranose (90)

0R2490P20 x1 004=15 7-MAR-88 21 3-8 88 47 20LHF EI+  
 Bp#0 1=2.0v Ha#0 TIC=41681888 Acnt MC Sus LREDIS  
 PT= 0° Cal: HCAL

HRK 1294/000  
 MASS 91




Fig. 21C Mass Spectrum of Methyl 3-N-(benzyl-carboxamido)-

2,3,4,6-tetra-deoxy-beta-DL-erythro-hexopyranose (90)

BP=91 I=3.0v H=494 TIC=109721000  
 ACC MASS

Met: SYS:MRP115  
 PT= 0° Cal: DR249UP

| Wt% | C | H | N | O | FW | DBE | OBS. MASS |
|-----|---|---|---|---|----|-----|-----------|
| 12  |   |   |   |   |    |     |           |

|     |    |    |   |   |      |     |             |
|-----|----|----|---|---|------|-----|-------------|
| 249 | 15 | 23 | 1 | 2 | 1.1  | 5.0 | 249.1718140 |
| 234 | 14 | 20 | 1 | 2 | -2.2 | 5.5 | 234.1515660 |
| 218 | 14 | 20 | 1 | 1 | 0.1  | 5.5 | 218.1544340 |
| 186 | 4  | 10 | 0 | 3 | -2.0 | 0.0 | 186.0658330 |
| 120 | 5  | 12 | 0 | 3 | -1.0 | 0.0 | 120.0796360 |
| 91  | 7  | 7  | 0 | 0 | 1.8  | 4.5 | 91.0530090  |





Fig. 22D

High Resolution Mass Spectrum of 3-N-(benzylamino-  
 methyl)-2,3,4,6-tetraoxy- $\beta$ -D-erythro-  
 hexopyranose (90)






Fig. 22A I.R. Spectrum of 3-N-(benzylamino-methyl)-2,3,4,6-tetra-deoxy- $\alpha$ -DL-erythro-hexopyranose (90)



PPK

YAN2.001  
AU PROG:  
AUTOH1  
DATE 10-3-88

SF 300.133  
SY 112.350000  
O1 3250.000  
S1 32768  
S2 32768  
SM 5000.000  
HZ/PT .305  
PM 6.0  
RD 4.000  
AQ 3.277  
RG 16  
NS 32  
TE 300  
FW 6300  
O2 3205.000  
DP 60L D0

LB .100  
GB .600  
CX 37.00  
CY 18.50  
F1 8.997P  
F2 .248P  
HZ/CM 74.991  
PPM/CM .250  
SR 3367.11

7.328  
7.327  
7.326  
7.325

3.7961  
3.4390  
3.3140

1.1701  
1.1490

YAN-2 1-H AT 300 MHZ IN CDCL3





Fig. 22B P.M.R. Spectrum of 3-N-(benzylamino-methyl)-  
2,3,4,6-tetra-deoxy-α-DL-erythro-hexopyranose (90)




Fig. 22C  
 Mass Spectrum of 3-N-(benzylamino-methyl)-2,3,4,6-tetra-deoxy- $\alpha$ -DL-erythro-hexopyranose (90)

## REFERENCE

- (1) C.M. Wong; Yulin Yan and H-Y.P. Lam; Kangshengsu (Chinese Journal of Antibiotics), 11 (5): 398-409, (1986).
- (2) a) F. Arcamone; A. Di. Marco; M. Gaettani and T. Scotti. G.; Microbiol, 83: 9 (1961).  
b) H. Brockmann; "Pyrromycines and pyrromicinones. Rhodomycines and Rhodomycinones", Sostanze Natural, 33-51 (1961), Acead. Nazl. Lincei, Rome.
- (3) H. Brockmann; Fortschr; Chem. Organ. Naturst., 21: 121, (1963).
- (4) a) G. Cassinelli and P. Orezzi; G. Microbiol. 11: 167, (1963).  
b) M. Dubost; P. Ganter; R. Maral; L. Ninet; S. Pinnert; J. Prend'Homme and G. H. Werner, C. R. Acad. Sci., 257: 1813, (1963).  
c) F. Arcamone; "Doxorubicin anticancer antibiotics", Academic press., (1981).
- (5) F. Arcamine; G. Cassinelli; G. Famtirri; A. Grein; P. Orezzi; C. Pol and C. Spalla; Biotechnol. Bioeng., 11: 1101, (1969).
- (6) T. Oki; Y. Matsuzawa; A. Yoshimoto; K. Numata; I. Kitamura; S. Hori; A. Takamatsu; H. Umezawa; M. Ishizaka; H. Naganawa; H. Suda; M. Hamada and T. Takeuchi; J. Antibiotics, 28: 830, (1975).
- (7) Pettit, G. R.; Dreerle, R. H.; Brown, P.; Brazhnikova, M. C. and Gause, G. F.; J. Am. Chem. Soc., 97 (25): 7387-7388, (1975).

- (8) Lunel, J. and Preud'homme, J.; Ger. Offen. 1,911,240, (cl. Co7c, A 61k), 02, Oct., 1969, (C. A., 72: 20603p, (1970).
- (9) a) R. H. Blum and S. K. Carter; ANN. Intern. Med., 80: 249, (1974).  
b) E. A. Lefrak; J. Pitha; S. Rosenheim and J. A. Gottlieb; Cancer, 32: 302 (1973).  
c) L. Lenaz and J. A. Pafe; Cancer Treat. Rev., 3: 111 (1976).
- (10) Mcguire, W. P.; Cancer Treat. Rep. 62, 855-863, (1978).
- (11) W. J. Pigram; W. Fuller and L. D. Hamilton; Nature New Bio., 235(5): 17, (1972).
- (12) H. W. Moore; Science, 197: 527, (1977).
- (13) a) T. R. Tritton and G. Yee; Science, 217: 248, (1982).  
b) E. Goormaghtigh and J. M. Ruysschaert, Biochemica, Biophys. Acta., 271-282, 1984.
- (14) Andrew, H-J. Wong; Giovanni Ughetto; Gary J. Quigley; and Alexander Rich; Biochemistry, 26, 1152-1163, (1987).
- (15) F. Arcamone; G. Cassinelli; G. Francesch; R. Mondelli; P. Orezzi and S. Penco; Gazz. Chim. Ztal., 100: 49, (1979).
- (16) Casazza, A. M.; Cancer Treat. Rep., 63, 835-844, (1979).
- (17) a) Bachmann, E. and Zbinden, G.; Toxicol. Lett., 3, 29-34, (1979).  
b) Gosalvez, M.; Blanco, M.; Hunter, J.; Miko, M.; and Chance, B.; Eur. J. Cancer, 10, 657-674, (1974).  
c) Goormaghtigh, E.; Pollakis, G.; and Ruysschaert; J. M.; Biochem. Pharmacol., 32, 889-893, (1983).

- d) Carlo Bianchi; Anna Bagnato; Marco G. Paggi; and Aristide Floridi; *Experimental and Molecular Pathology*, 46, 123-135, (1987).
- (18) a) N. R. Bachur; S. L Gordon and M. V. Gee; *Mol. Pharmacol.*, 13: 901, (1977).  
b) C. Winterborn; *FEBS Lett.*, 136: 89, (1981).  
d) P. H. Hochstem. *Biochem. Biophys. Res.*, 77: 797, (1977).  
e) N. R. Bachur; *Cancer Res.*, 38: 1945, (1978).
- (19) J. Westendorf; H. Marquardt; and H. Marquardt; *Cancer Research*, 44, 5599-5604, (1984).
- (20) Henry, D. W.; *Cancer Treat. Rep.*, 63, 845-854, (1979).
- (21) a) L. Tong; D. W. Henry and E. M. Acton; *J. Med. Chem.*, 22: 36, (1979).  
b) J. W. Lown; H-H. Chen et al.; *Biochem. Pharmacol.*, 27: 1, (1979).
- (22) C. M. Wong; W. Haque; H-Y Lam; K. Marat; E. Bock and A. Q. Mi; *Can. J. Chem.*, 61, 1788, (1983).
- (23) K. Krohb; H. H. Ostermeyer and K. Tolkien; *Chem. Ber.*, 112: 3453, (1979).
- (24) S. Neidle and G. Taylor; *Biochem. Biophys. Acta*, 479: 450, (1977).
- (25) a) F. Acarmone; L. Bernardi; B. Patelli; P. Giardino; A. Di. Marco; A. M. Casazza; C. Soranzo and G. Pratesi; *Experientia*, 34: 1255, (1978).  
b) A. Di. Marco; A. M. Casazza et al.; *Cancer Chemother. Pharmacol.*, 1: 249, (1978).

- (26) Boeckman, R R JR; Sum F-W.; J. Am. Chem. Soc., 104: (17), 4605-4610, (1982).
- (27) Kende As; Rizzi J. P.; Tetra. Lett., 22: (19), 1779-1782, (1981).
- (28) Contalone P. N; Pizzolato, G.; J. Am. Chem. Soc., 103: (14), 4251-4254, (1981).
- (29) Tsung-tee Li and Yu lin Wu; J. Am. Chem. Soc., 103 (23), (1981).
- (30) M. J. Broadhurst; C. H. Hassalli; J. Chem. Soc., "Perkin Trans I", 9: 2227-2238, (1982).
- (31) S. Penco; A. M. Casazza, et al; Cancer Treatment Reports, 67(7-8): 665-673, (1983).
- (32) S. Penco; F. Angelucci; F. Arcamone; M. Ballabio; G. Barchielli; G. Franceschi; G. Franchi; A. Suarato; and E. Vanotti; J. Org. Chem., 48(3): 405-406, (1983).
- (33) C. M. Wong; Qi-Qiao Mi; Jiali Ren; W. Haque and K. Marat; Tetrahedron, 40(22): 4789-4795, (1984).
- (34) F. M. Hanster and Dipakranjan Mal; J. Am. Chem. Soc., 106: 1098-1104, (1984).
- (35) J. F. Honek; Michael L Mancini and Bernard Belleau; Synthetic Communications, 13(12): 977-983, (1983).
- (36) Z. Abmed and M. P. Cava; Tetrahedron letters, 22(52): 5339-5242, (1981).
- (37) C. M. Wong; D. Popien; R. Schwenk; and J. TeRaa; Can. J. Chem., 49, 2712, (1971).
- (38) Wong, C. M.; Gordon, P. M.; Chen, A. G.; Lam, H. Y. P.; Can. J. Chem., 65(6): 1375-1379, (1987).

- (39) a) F. Zunino; R. A. Gambetta; A. Dimarco; and A. Zaccarra; Biochem. Biophys. Acta, 277:489, (1972).  
b) Gabbay, E. J.; Grier, D.; Fingerle, R. E. Reimer; R., Lery, R, Pearce, S. W.; and Wilson, W. D.; Biochemistry, 15: 2062-2070, (1976).
- (40) a) A. Di. Marco; A. M. Casazza; R. Gambetta; R. Supino; and F. Zunino; Cancer Res., 36: 1962, (1976).  
b) E. F. Fuchs; D. Horton; W. Weckerle and B. Winter; J. Antibiot., 32: 233, (1979).
- (41) a) F. Arcamone; S. Penco; S. Redaelli; S. Hanessian; J. Med. Chem., 19(12): 1424-1425, (1976).  
b) F. Arcamone; sergio penco; A. Vigevani; S. Redaelli; G. Franchi; A. D. Marco; A. M. Casazza; T. Dasdia; F. Formell; A. Necco; and C. Soranzo; J. Med. Chem., 3: 70, 44, (1975).
- (42) a) F. Arcamone; S. Penco; S. Redaelli et al.; J. Med. Chem., 19: 1424, (1976).  
b) F. Arcamone; Ade. Med. Oncol. Res. Edac., 5: 21 (1979).
- (43) W. R. Bachur; Cancer Res., 38: 1954 (1978).
- (44) G. Zbinden; M. Pfister and C. Holderegger; Toxicol. Lett., 1: 267, (1978).
- (45) a) M. Ogawa et al.; Cancer Treat. Rep., 63: 931, (1979).  
b) H. Umezawa et al.; J. Antibiot., 1978.
- (46) E. F. Fuchs; D. Horton; W. Wecherle and B. Winter; J. Antibiot., 32: 203, (1979).
- (47) C. M. Wong; T-L Ho and W. P. Niemczura; Can. J. Chem., 53: 3144, (1975).

- (48) H-K Hung; H-Y Lam; W. Niemczuza; M-C Wang and C. M. Wong; *Can. J. Chem.*; 56: 638-644, (1978).
- (49) a) Dyong, I.; Weimann, R.; *Angew. Chem. Int. Ed. Engl.* 17: 682, (1978).  
b) Hauser, F. M.; Rhee, R. P.; *J. Org. Chem.* 46: 227, (1981).  
c) Deshong, P.; Leginus, J. M.; *J. Am. Chem. Soc.*, 105: 1686, (1983).
- (50) Dyong, I.; Wiemann, R.; *Chem. Ber.* 113, 2666, (1980).
- (51) Marsh, J. P.; Mosher, C. W.; Acton, E. M.; Goodman, L.; *J. Chem. Commun.*, 973, (1967).
- (52) D. Horton and W. Weckerle; *Carbohy. Res.* 44, 227-240, (1975).
- (53) Fronza, G.; Fuganti, C.; Grasselli, P.; *J. Chem. Soc., Chem. Commun.*, 442, (1980).
- (54) a) Fuganti, C.; Grasselli, P.; Fantoni, P.; *Tetrahedron Lett.*, 4017, (1981).  
b) D. Horton and W. Weckerle; *Carbohy. Res.*, 44, 227-240, (1975).
- (55) J. P. Marsh; Jr. C. W. Mosher; E. M. Acton; and L. Goodman; *Chem. Commun.*, 973-975, (1967).
- (56) a) F. Acarbone; "Adriamycin-antitumor antibiotics", Academic press., 196-255 (1981).  
b) A. Martin; "Mary pairs and claude Monneret." *J. Chem. Soc. Chem. Commun.*, 6, 305-306, (1983).  
c) A. Warm and P. Vogel; *J. Org. Chem.*, 51: 1751, (1980).  
d) H. H. Baer and H. R. Hanna; *Can. J. Chem.*, 58: 1751, (1980).

- e) Hassan S. Elkhadem; David L. Swartz et al.; Carbohydrate Research, 58: 230-234, (1977).
- (57) P. M. Wovkulich; and M. R. Uskokovic; J. Am. Chem. Soc., 103: 3956, (1981).
- (58) a) F. M. Hauser; R. P. Rhee; and S. R. Ellenberger; J. Org. Chem., 49, 2236-2240, (1984).  
b) Servi, Stefano; J. Org. Chem., 50 (26), 5865-5867, (1985).
- (59) F. M. Hauser and S. R. Ellenberger; J. Org. Chem., 51, 50-57, (1986).
- (60) A. Warm and P. Vogel; J. Org. Chem. 51, 5348-5358, (1986).
- (61) E. M. Acton; A. N. Fujjwara; D. W. Henry; J. Med. Chem., 17(6): 659-666, (1974).
- (62) a) F. Arcamone; A. Bargiotti; A. D. Marco, S. Penco; Ger. Offen., 2,618,822 (cl. Co7H 15/24), 11 Nov., 1976, (C. A., 86: 140416, 1977).  
b) F. Arcamone; S. Penco; S. Redaelli et al.; J. Med. Chem., 19: 1424, (1976).  
c) H. Tanaka; T. Yoshioka; Y. Shimauchi; A. Yoshimoto; T. Ishikura; H. Naganana; T. Takeuchi and H. Umezawa; Tetrahedron Lett., 25(31): 3355-3358, (1984).
- (63) B. A. Pearman; J. M. McNamara; I. Hasan; S. Hatakeyama; H. Sekizaki; and Y. Kishi; J. Am. Chem. Soc., 123(14): 4248-4251, (1981).
- (64) Oki. T; Yoshimoto. A; Matsuzawa. Y; Takeuchi. T; Umezawa; H.; J. Antibiot., 33: 1331, (1980).

- (65) a) G. Cassinelli; F. D. Matteo; S. Forenza; M. C. Ripamonti; G. Rivola; F. Arcamone; A. D. Marco; A. M. Casazza; C. Soranzo and G. Pratesi; *J. Antibiot.*, 33: 1468, (1980).  
b) A. C. Dickinson et al.; *Biochem. and Biophys. Res.*, 125: 584 (1984).  
c) F. Arcamone; *Adv. Med. Oncol. Res. Educ.* 521 (1979).  
d) G. Mathe; M. Bayssas; J. Gouvcia et al.; *Cancer Chemother. Pharmacol.*, 1: 259, (1978).
- (66) Du Rong Sheng et al; *Kangshengsu (Chinese Journal of Antibiotics)*, 2: 108, (1982).
- (67) T. J. Gordon and C. M. Jackman; W. D. Ollis; and I. O. Sutherland; *Tetrahedron Letters*, 8: 28-34, (1960).
- (68) a) K. Eckardt; D. Tresselt and J. Tax; *Tetrahedron*, 30: 3787-3791, (1974).  
b) D. Tresselt; K. Eckardt and J. Tax; *Tetrahedron*, 31: 613-617, (1975).
- (69) P. Deslongchamps; "Stereo-electronic Effects in Organic Chemistry", (*Organic Chemistry Series*, vol. 1, Editor: J. E. Baldwin), page 5, 720, (1983).
- (70) T. H. Smith; A. W. Fujiware; W. W. Lee; Helen Y. Wu and D. W. Henry; *J. Org. Chem.*, 42: (23), 3653-3660, (1977).
- (71) a) T. Oki; Y. Matsuawa; A. Yoshimoto; K. Numata; I. Kitamura; S. Hori; A. Takamatsu; H. Umezawa; M. Ishizuka; H. Naganawa; H. Suda; M. Hamada; and T. Takenchi; *J. Antibiot.*, 28: 830, (1975).

- b) T. Oki; I. Kitamura; A. Yoshimoto; Y. Matsuzawa; N. Shibamoto; T. Ogasanra; T. Inui; A. Takamatsu; T. Takeuchi; T. Masuda; M. Hamada; H. suda; M. Ishizuka; T. Sawa; and H. Umezawa; *J. Antibiot.*, 32: 791 (1979).
- (72) F. Arcamone and S. Penco; *Cancer Chemother. Rep.*, 6: part 3, 123, (1975).
- (73) M. Dejter-Juszynski and H. M. Flowers; *Carbohydr. Res.*, 28: 61, (1973).
- (74) M. Dejter-Juszynski and H. M. Flowers; *Carbohydr. Res.*, 23: 41, (1972).
- (75) E. M. Acton; A. N. Fajiware; and D. W. Henry; *J. Med. Chem.*, 17: 659, (1974).
- (76) F. Arcamone; G. Cassinelli; G. Franceschi; P. Orezzi; R. Mondelli; *Tetrahedron Lett.*, 30: 3353, (1968).
- (77) a) R. G. Pearson and J. Songstad; *J. Am. Chem. Soc.*, 89:8, 1827-1836, (1967).
- b) R. G. Pearson; *J. Chem. Education*. 45(9), 581-587, (1968).
- c) S. Ahrland; *Chemical Physics Letters*, 2 (5) 303-306, (1968).
- d) S. Salille; *Angew. Chem. Internat. Edit.* 6(11), 365-376, (1967).
- (78) G. Kotowycz; T. Schaefer; and E. Bock; *Can. J. Chem.*, 42, 3541, (1964).
- (79) J. A. Pople; *Mol. Phys.*, 1: 168, (1958).
- (80) a) Eberhard Breitmaier and Gerhard Baier; <sup>13</sup>C NMR Spectroscopy: A Working Manual with Exercise, pp 56, 315, (1984).

- b) E. Breitmaier and W. Voelter;  $^{13}\text{C}$  NMR Spectroscopy: Methods and Application, Chapter 4, Chapter 5, 223-234, (1974).
- (81) K. Nakanishi; "Infrared Absorption Spectroscopy", Nankodo Company Limited, page 43, (1962).
- (82) S. Mizushima; J. Chem. Phys., 21: 815, (1953).
- (83) a) M. Bodanszky and M. A. Ondetti; Peptide Synthesis, Interscience, New York, 1966.
- b) Jerry March; Advanced Organic Chemistry, Third Edition, p. 1987-188, 669, (1985).
- (84) J. B. Lambert; H. F. Shurvell; L. Verbit; R. G. Cooks; and G. H. Stout; Organic Structural Analysis, (Collier Macmillan Publishers), page, 41-43, (1976).
- (85) S. W. Tobey; J. Org. Chem., 34, 1281, (1969).
- (86) S. J. Angyal, V. a. Pickles and R. Ahluwalia; Carbohydrate Res., 3, 300, (1967).
- (87) a) A. Gaudemer; "Determination of configurations by NMR Spectroscopy", Stereochemistry: Fundamental and Methods, Vol. 1, (Edited by Henri B. Kagan), page 102, (1977).
- b) J. F. Stoddart; "Stereochemistry of Carbohydrates", page 129-136, (1971).
- (88) A. Gaudemer; "Determination of configurations by NMR Spectroscopy", Stereochemistry: Fundamental and Methods, Vol. 1, (Edited by Henri B. Kagan), p. 118-121, (1977).
- (89) a) Alan Bassindale; The Third Dimension In Organic Chemistry, Chapter 14, (1984).

- b) A. Gaudemer; "Determination of configurations by NMR Spectroscopy", Stereochemistry: Fundamental and Methods, Vol. 1, (Edited by Henri B. Kagan), p. 118-121, (1977).
- (90) K. Umezawa et al; Cancer Res. 38, 1782, (1978).